<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Colistin (colistimethate): Drug information
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
<body>

            <section class=3D"course-details-area ptb-60">
            <div class=3D"container">

                  <div class=3D"uptodate2" style=3D"padding:50px 0px 50px 0=
px;direction: ltr;text-align: left;">
                                          <h1 style=3D"text-align:center">Colistin (colistimethate): Drug information</h1>
                        <div id=3D"topicContent" class=3D"utdArticleSection=
 utdStyle"><div id=3D"drugTitle">Colistin (colistimethate): Drug informatio=
n</div><div class=3D"clear"></div><div id=3D"topicText">(For additional inf=
ormation <a data-topicid=3D"10898" class=3D"drug drug_patient" rel=3D"exter=
nal" href=3D"/d/html/10898">see "Colistin (colisti=
methate): Patient drug information"</a> and <a data-topicid=3D"13161" class=
=3D"drug drug_pediatric" rel=3D"external" href=3D"/d/html/13161">see "Colistin (colistimethate): Pediatric drug information"<=
/a>)<br><br>For abbreviations, symbols, and age group definitions used in L=
exicomp (<a class=3D"graphic graphic_table" rel=3D"external" href=3D"/d/html/57469">show table</a>)<div id=3D"formulinkBodyPl=
aceholder" class=3D"visuallyHidden drugH1Div"><span class=3D"drugH1"></span=
></div>
<div id=3D"F154558" class=3D"list ubnlist drugH1Div drugBrandNames"><span c=
lass=3D"drugH1">Brand Names: US</span>
                  <ul>
                     <li>Coly-Mycin M</li></ul></div>
<div id=3D"F52866437" class=3D"list canbnlist drugH1Div drugBrandNames"><sp=
an class=3D"drugH1">Brand Names: Canada</span>
                  <ul>
                     <li>Coly-Mycin M</li></ul></div>
<div id=3D"F154573" class=3D"ex_sect_xr thclist drugH1Div drugBrandNames"><=
span class=3D"drugH1">Pharmacologic Category</span>
                  <ul>
                     <li>
                        Antibiotic, Miscellaneous</li></ul></div>
<div id=3D"F154561" class=3D"block doa drugH1Div"><span class=3D"drugH1">Do=
sing: Adult</span>
                  <p style=3D"text-indent:0em;display:inline">
                     <b>Note:</b> Reserve for extensively drug-resistant gr=
am-negative infections (eg, carbapenem-resistant <i>Enterobacterales</i> or=
 <i>A. baumannii</i>, difficult to treat <i>P. aeruginosa</i>) when other a=
gents cannot be used (<span class=3D"ref-callout-list"><a class=3D"ref-call=
out-list-link" lexi-content-ref-id=3D"['lexi-content-ref-30710469']" aria-l=
abel=3D"list of references">Ref</a></span>). Dosage expressed in terms of <=
b>mg</b> of <b>colistin base activity (CBA). CBA 1 mg </b>is defined to be =
equivalent to <b>colistimethate sodium (CMS) 30,000 units</b> which is equi=
valent to <b>~2.4 mg CMS</b> (see table below) (<span class=3D"ref-callout-=
list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-cont=
ent-ref-EMA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lex=
i-content-ref-23728146','lexi-content-ref-24107410','lexi-content-ref-28011=
614']" aria-label=3D"list of references">Ref</a></span>).</p>
                  <table border=3D"1" rules=3D"all" frame=3D"border">
                     <caption style=3D"text-align:center;">
                        <b>Colistimethate Sodium Conversion (EMA 2014)</b><=
/caption>
                     <colgroup><col align=3D"center">
                     <col align=3D"center">
                     <col align=3D"center">
                     </colgroup><tbody>
                        <tr>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">Colistimethate =
Sodium</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">Colistimethate =
Sodium</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">Colistin-Base A=
ctivity</p></td></tr>
                        <tr>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">12,500 units</p=
></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">1 mg</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">0.4 mg</p></td>=
</tr>
                        <tr>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">150,000 units</=
p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">12 mg</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">5 mg</p></td></=
tr>
                        <tr>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">1,000,000 units=
</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">80 mg</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">34 mg</p></td><=
/tr>
                        <tr>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">4,500,000 units=
</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">360 mg</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">150 mg</p></td>=
</tr>
                        <tr>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">9,000,000 units=
</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">720 mg</p></td>
                           <td align=3D"center">
                              <p style=3D"text-indent:0em;">300 mg</p></td>=
</tr></tbody></table>
                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"8f9ec9fd-fc1b-4a1f-868a-ee=
b97c396e6e" class=3D"collapsible-indication-title">Bloodstream infection</s=
pan>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Bloodstream infection:</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> When polymyxin use is warranted, po=
lymyxin B is preferred over colistimethate due to significant interpatient =
variability in pharmacokinetics, slower attainment of desired plasma concen=
trations, and increased risk of nephrotoxicity with colistimethate (<span c=
lass=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-r=
ef-id=3D"['lexi-content-ref-30710469','lexi-content-ref-35439291']" aria-la=
bel=3D"list of references">Ref</a></span>). To minimize development of resi=
stance, use in combination with other antibiotics, depending on infection s=
ite and susceptibilities (<span class=3D"ref-callout-list"><a class=3D"ref-=
callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-25630411','lex=
i-content-ref-30710469','lexi-content-ref-25461655']" aria-label=3D"list of=
 references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>IV: </b>300 mg colistin base activity (CBA) l=
oading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi=
-content-ref-19433570']" aria-label=3D"list of references">Ref</a></span>).=
 Usual duration is 7 to 14 days depending on source, extent of infection, a=
nd clinical response (<span class=3D"ref-callout-list"><a class=3D"ref-call=
out-list-link" lexi-content-ref-id=3D"['lexi-content-ref-34738022','lexi-co=
ntent-ref-30535100']" aria-label=3D"list of references">Ref</a></span>).</p=
></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"52c697f3-429c-4126-a68e-17=
db9149a21e" class=3D"collapsible-indication-title">Bronchiectasis, exacerba=
tion prevention</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Bronchiectasis, exacerbation prevention (off-=
label use):</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> Reserve for patients with multidrug=
-resistant gram-negative pathogens in the sputum and either &gt;3 exacerbat=
ions per year or severe exacerbations (<span class=3D"ref-callout-list"><a =
class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-B=
arker.1','lexi-content-ref-28889110']" aria-label=3D"list of references">Re=
f</a></span>). Dose not well defined and varies widely across studies.</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Inhalation for nebulization (off-label route)=
:</b> 30 to 150 mg colistin base activity (CBA) via nebulizer once or twice=
 daily (maximum dose: 150 mg CBA twice daily) (<span class=3D"ref-callout-l=
ist"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-conte=
nt-ref-28889110','lexi-content-ref-24625200','lexi-content-ref-20500046','l=
exi-content-ref-19436571','lexi-content-ref-17547727']" aria-label=3D"list =
of references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"df85d498-37b3-4d24-95e1-d4=
a9ea8cb8c0" class=3D"collapsible-indication-title">Cystic fibrosis</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Cystic fibrosis (off-label use):</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <i>Acute pulmonary exacerbation:</i>
                           <b> Note:</b> To minimize development of resista=
nce, use in combination with other antibiotics depending on susceptibilitie=
s (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi=
-content-ref-id=3D"['lexi-content-ref-25630411','lexi-content-ref-30710469'=
,'lexi-content-ref-25461655']" aria-label=3D"list of references">Ref</a></s=
pan>).</p>
                        <p style=3D"text-indent:-2em;margin-left:6em;">
                           <b>IV:</b> 2.5 to 5 mg/kg/day colistin base acti=
vity (CBA) in 3 divided doses. Maximum dose not well defined (<span class=
=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-i=
d=3D"['lexi-content-ref-35678460','lexi-content-ref-UKCF.1','lexi-content-r=
ef-22949160']" aria-label=3D"list of references">Ref</a></span>); some expe=
rts suggest a maximum of 300 mg CBA/day in patients with cystic fibrosis (<=
span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-con=
tent-ref-id=3D"['lexi-content-ref-Simon.1']" aria-label=3D"list of referenc=
es">Ref</a></span>). Treatment duration is 10 to 14 days depending on patie=
nt-specific factors, including initial response to therapy (<span class=3D"=
ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D=
"['lexi-content-ref-34469706']" aria-label=3D"list of references">Ref</a></=
span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <i>Chronic P. aeruginosa pulmonary infection: </=
i>
                           <b>Inhalation for nebulization (off-label route)=
:</b> 75 to 150 mg CBA via nebulizer twice daily (<span class=3D"ref-callou=
t-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-co=
ntent-ref-20500046','lexi-content-ref-Simon.2']" aria-label=3D"list of refe=
rences">Ref</a></span>). Administer in repeated cycles of 28 days on drug f=
ollowed by 28 days off drug (<span class=3D"ref-callout-list"><a class=3D"r=
ef-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-32115388','=
lexi-content-ref-23540878','lexi-content-ref-Simon.2']" aria-label=3D"list =
of references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"485d58ca-9e0e-4284-8228-d5=
5fd4f946ff" class=3D"collapsible-indication-title">Intra-abdominal infectio=
n</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Intra-abdominal infection:</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> When polymyxin use is warranted, po=
lymyxin B is preferred over colistimethate due to significant interpatient =
variability in pharmacokinetics, slower attainment of desired plasma concen=
trations, and increased risk of nephrotoxicity with colistimethate (<span c=
lass=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-r=
ef-id=3D"['lexi-content-ref-30710469','lexi-content-ref-35439291']" aria-la=
bel=3D"list of references">Ref</a></span>). To minimize development of resi=
stance, use in combination with other antibiotics, depending on infection s=
ite and susceptibilities (<span class=3D"ref-callout-list"><a class=3D"ref-=
callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-25630411','lex=
i-content-ref-30710469','lexi-content-ref-25461655']" aria-label=3D"list of=
 references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>IV: </b>300 mg colistin base activity (CBA) l=
oading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi=
-content-ref-19433570']" aria-label=3D"list of references">Ref</a></span>).=
 Total duration of therapy (which may include transition to oral antibiotic=
s) is 4 to 5 days following adequate source control (<span class=3D"ref-cal=
lout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi=
-content-ref-25992746','lexi-content-ref-28085573']" aria-label=3D"list of =
references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"90b4bed4-9c84-419c-9067-b0=
892c7eeb49" class=3D"collapsible-indication-title">Meningitis, bacterial</s=
pan>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Meningitis, bacterial:</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> When systemic polymyxin use is warr=
anted, polymyxin B is preferred over colistimethate due to significant inte=
rpatient variability in pharmacokinetics, slower attainment of desired plas=
ma concentrations, and increased risk of nephrotoxicity with colistimethate=
 (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-=
content-ref-id=3D"['lexi-content-ref-30710469','lexi-content-ref-35439291']=
" aria-label=3D"list of references">Ref</a></span>). To minimize developmen=
t of resistance, use in combination with other antibiotics, depending on in=
fection site and susceptibilities (<span class=3D"ref-callout-list"><a clas=
s=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-25630=
411','lexi-content-ref-30710469','lexi-content-ref-25461655']" aria-label=
=3D"list of references">Ref</a></span>). Intraventricular/intrathecal admin=
istration is generally reserved for meningitis or ventriculitis that is ref=
ractory to appropriate parenteral therapy or associated with intraventricul=
ar devices that cannot be removed (<span class=3D"ref-callout-list"><a clas=
s=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-Baddo=
ur.1']" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>IV:</b> 300 mg colistin base activity (CBA) l=
oading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi=
-content-ref-19433570']" aria-label=3D"list of references">Ref</a></span>).=
 Treatment duration is =E2=89=A510 to 14 days (<span class=3D"ref-callout-l=
ist"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-conte=
nt-ref-28203777']" aria-label=3D"list of references">Ref</a></span>); some =
experts recommend =E2=89=A521 days (<span class=3D"ref-callout-list"><a cla=
ss=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-1549=
4903']" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Intrathecal/intraventricular (adjunctive agen=
t) (off-label route) (use a preservative-free preparation):</b> 4.2 mg CBA =
per day in 1 or 2 divided doses; administer in combination with appropriate=
 systemic antimicrobial therapy (<span class=3D"ref-callout-list"><a class=
=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-307104=
69','lexi-content-ref-28203777','lexi-content-ref-22687507','lexi-content-r=
ef-23335739']" aria-label=3D"list of references">Ref</a></span>). <b>Note:<=
/b> When intraventricular colistimethate is administered via a ventricular =
drain, clamp drain for 15 to 60 minutes after administration (allows soluti=
on to equilibrate in cerebrospinal fluid) (<span class=3D"ref-callout-list"=
><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-r=
ef-15494903','lexi-content-ref-28203777']" aria-label=3D"list of references=
">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"58f09831-e1d9-4d13-a555-41=
96b8a7ce81" class=3D"collapsible-indication-title">Pneumonia, hospital-acqu=
ired or ventilator-associated</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Pneumonia, hospital-acquired or ventilator-as=
sociated:</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> When systemic polymyxin use is warr=
anted, polymyxin B is preferred over colistimethate due to significant inte=
rpatient variability in pharmacokinetics, slower attainment of desired plas=
ma concentrations, and increased risk of nephrotoxicity with colistimethate=
 (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-=
content-ref-id=3D"['lexi-content-ref-30710469','lexi-content-ref-35439291']=
" aria-label=3D"list of references">Ref</a></span>). To minimize developmen=
t of resistance, use in combination with other antibiotics, depending on in=
fection site and susceptibilities (<span class=3D"ref-callout-list"><a clas=
s=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-25630=
411','lexi-content-ref-30710469','lexi-content-ref-25461655']" aria-label=
=3D"list of references">Ref</a></span>). Some experts prefer to add inhaled=
 colistimethate for patients with serious hospital-acquired or ventilator-a=
ssociated pneumonia that requires treatment with IV colistimethate due to l=
ow lung concentrations with IV administration (<span class=3D"ref-callout-l=
ist"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-conte=
nt-ref-Kanafani.1']" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>IV:</b> 300 mg colistin base activity (CBA) l=
oading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi=
-content-ref-19433570']" aria-label=3D"list of references">Ref</a></span>).=
 Duration of therapy varies based on disease severity and response to thera=
py; treatment is typically given for 7 days (<span class=3D"ref-callout-lis=
t"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content=
-ref-27418577']" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Inhalation for nebulization (adjunctive agent=
) (off-label route):</b> Dose not well defined: 75 to 150 mg CBA twice dail=
y in combination with systemic antimicrobial therapy (<span class=3D"ref-ca=
llout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lex=
i-content-ref-24274315','lexi-content-ref-30710469','lexi-content-ref-27418=
577','lexi-content-ref-20876621','lexi-content-ref-25493971']" aria-label=
=3D"list of references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"a74533c8-554a-440e-8601-6b=
5e9cffeae7" class=3D"collapsible-indication-title">Sepsis and septic shock<=
/span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Sepsis and septic shock:</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note:</b> When polymyxin use is warranted, po=
lymyxin B is preferred over colistimethate due to significant interpatient =
variability in pharmacokinetics, slower attainment of desired plasma concen=
trations, and increased risk of nephrotoxicity with colistimethate (<span c=
lass=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-r=
ef-id=3D"['lexi-content-ref-30710469','lexi-content-ref-35439291']" aria-la=
bel=3D"list of references">Ref</a></span>). To minimize development of resi=
stance, use in combination with other antibiotics, depending on infection s=
ite and susceptibilities (<span class=3D"ref-callout-list"><a class=3D"ref-=
callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-25630411','lex=
i-content-ref-30710469','lexi-content-ref-25461655']" aria-label=3D"list of=
 references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>IV: </b>300 mg colistin base activity (CBA) l=
oading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi=
-content-ref-19433570']" aria-label=3D"list of references">Ref</a></span>);=
 use in combination with other appropriate agents. Initiate therapy as soon=
 as possible and preferably within 1 hour of recognition of sepsis or septi=
c shock. Duration is dependent on underlying source and patient response; s=
hort courses are preferred, when appropriate. Discontinue if a noninfectiou=
s etiology is identified (<span class=3D"ref-callout-list"><a class=3D"ref-=
callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-34599691']" ar=
ia-label=3D"list of references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"c3dbb92e-1e0f-40e8-92cb-d0=
cf047a674d" class=3D"collapsible-indication-title">Urinary tract infection,=
 complicated</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Urinary tract infection, complicated (pyelone=
phritis or urinary tract infection with systemic signs/symptoms):</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note: </b>Colistimethate is the preferred pol=
ymyxin for urinary tract infections because of higher urinary concentration=
s compared to polymyxin B (<span class=3D"ref-callout-list"><a class=3D"ref=
-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-30710469','le=
xi-content-ref-34864936','lexi-content-ref-35439291']" aria-label=3D"list o=
f references">Ref</a></span>). To minimize development of resistance, may u=
se in combination with other antibiotics, depending on susceptibilities (<s=
pan class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-cont=
ent-ref-id=3D"['lexi-content-ref-25630411','lexi-content-ref-30710469','lex=
i-content-ref-25461655']" aria-label=3D"list of references">Ref</a></span>)=
.</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>IV:</b> 300 mg colistin base activity (CBA) l=
oading dose followed 12 hours later with 150 to 180 mg CBA twice daily (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-22423120','lexi-content-ref-30710469','lexi=
-content-ref-19433570']" aria-label=3D"list of references">Ref</a></span>).=
 Total duration of therapy ranges from 5 to 14 days; for patients with symp=
tomatic improvement within the first 48 to 72 hours of therapy, some expert=
s recommend shorter courses of 7 to 10 days (<span class=3D"ref-callout-lis=
t"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content=
-ref-Gupta.1','lexi-content-ref-21292654','lexi-content-ref-30535100']" ari=
a-label=3D"list of references">Ref</a></span>).</p></div>
</div>

                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Dosage adjustment for concomitant therapy: </b>Sign=
ificant drug interactions exist, requiring dose/frequency adjustment or avo=
idance. Consult drug interactions database for more information.</p></div>
<div id=3D"F50991865" class=3D"block dora drugH1Div"><span class=3D"drugH1"=
>Dosing: Kidney Impairment: Adult</span>
                  <p style=3D"text-indent:0em;">The renal dosing recommenda=
tions are based upon the best available evidence and clinical expertise. Se=
nior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Robe=
rts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Note:</b> Dosage expressed in terms of <b>colistin =
base activity (CBA);</b> although reported conversions have varied slightly=
 in the literature,<b> CBA 1 mg </b>is defined to be equivalent to<b> colis=
timethate sodium 30,000 units</b> (<span class=3D"ref-callout-list"><a clas=
s=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-EMA.1=
','lexi-content-ref-16723606','lexi-content-ref-23728146','lexi-content-ref=
-24107410','lexi-content-ref-28011614']" aria-label=3D"list of references">=
Ref</a></span>). These dosing recommendations should achieve a target avera=
ge colistin steady-state plasma concentration of 2 mg/L and are derived fro=
m analysis of pharmacokinetic data in critically ill patients (<span class=
=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-i=
d=3D"['lexi-content-ref-28011614']" aria-label=3D"list of references">Ref</=
a></span>). For inhaled, intrathecal, and intraventricular colistin, there =
are no specific dosage adjustments recommended (has not been studied); howe=
ver, need for adjustment unlikely due to low systemic absorption (<span cla=
ss=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref=
-id=3D"['lexi-content-ref-Expert.DOR']" aria-label=3D"list of references">R=
ef</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Altered kidney function:</b></p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Loading do=
se: <b>IV:</b> 300 mg CBA, followed by a maintenance dose based on CrCl (<s=
pan class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-cont=
ent-ref-id=3D"['lexi-content-ref-30710469','lexi-content-ref-28011614']" ar=
ia-label=3D"list of references">Ref</a></span>) calculated using the Cockcr=
oft-Gault equation with an adjusted body weight (ideal body weight [IBW] + =
0.4 [total body weight =E2=80=93 IBW]) (<span class=3D"ref-callout-list"><a=
 class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-=
30710469','lexi-content-ref-28011614','lexi-content-ref-22576791']" aria-la=
bel=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Maintenanc=
e dose: <b>IV:</b> The following total daily maintenance doses (administere=
d in 2 divided doses) are recommended (<span class=3D"ref-callout-list"><a =
class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-3=
0710469','lexi-content-ref-28011614']" aria-label=3D"list of references">Re=
f</a></span>); begin maintenance dose 12 hours after the loading dose:</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl =E2=
=89=A590 mL/minute: 360 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 80 to=
 &lt;90 mL/minute: 340 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 70 to=
 &lt;80 mL/minute: 300 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 60 to=
 &lt;70 mL/minute: 275 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 50 to=
 &lt;60 mL/minute: 245 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 40 to=
 &lt;50 mL/minute: 220 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 30 to=
 &lt;40 mL/minute: 195 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 20 to=
 &lt;30 mL/minute: 175 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 10 to=
 &lt;20 mL/minute: 160 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 5 to =
&lt;10 mL/minute: 145 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl &lt;5=
 mL/minute: 130 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;margin-top:2=
em;">
                     <b>
                        <i>Alternative renal dosing strategy (<span class=
=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-i=
d=3D"['lexi-content-ref-EMA.1','lexi-content-ref-26607424']" aria-label=3D"=
list of references">Ref</a></span>):</i></b></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>IV:</b></p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">For critic=
ally ill patients, a loading dose of 300 mg CBA should be administered foll=
owed by a maintenance dose based on CrCl. The following total daily mainten=
ance doses (administered in 2 or 3 divided doses) are recommended; begin ma=
intenance dose 12 hours after the loading dose:</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl =E2=
=89=A550 mL/minute: 300 mg CBA/day; patients with good kidney function (CrC=
l =E2=89=A580 mL/minute) may require higher doses &gt;300 mg/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 30 to=
 &lt;50 mL/minute: 183 to 250 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl 10 to=
 &lt;30 mL/minute: 150 to 183 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">CrCl &lt;1=
0 mL/minute: 117 mg CBA/day.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;margin-top:2=
em;">
                     <b>Augmented renal clearance (measured urinary CrCl =
=E2=89=A5130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (=
ARC) is a condition that occurs in certain critically ill patients without =
organ dysfunction and with normal serum creatinine concentrations. Young pa=
tients (&lt;55 years of age) admitted post trauma or major surgery are at h=
ighest risk for ARC, as well as those with sepsis, burns, or hematologic ma=
lignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify=
 these patients (<span class=3D"ref-callout-list"><a class=3D"ref-callout-l=
ist-link" lexi-content-ref-id=3D"['lexi-content-ref-29441476','lexi-content=
-ref-20000886']" aria-label=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <b>IV:</b> 360 mg CBA/day (<span class=3D"ref-callout-=
list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-cont=
ent-ref-Expert.DOR']" aria-label=3D"list of references">Ref</a></span>).</p=
>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <b>Note:</b> No definitive studies have evaluated coli=
stin pharmacokinetics in ARC. Patients with ARC receiving conventional dose=
s required longer treatments than those without ARC (<span class=3D"ref-cal=
lout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi=
-content-ref-30709064']" aria-label=3D"list of references">Ref</a></span>).=
</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Hemodialysis, intermittent (thrice weekly):</b> Dia=
lyzable (~30%) (<span class=3D"ref-callout-list"><a class=3D"ref-callout-li=
st-link" lexi-content-ref-id=3D"['lexi-content-ref-25698772']" aria-label=
=3D"list of references">Ref</a></span>):</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Loading do=
se: <b>IV:</b> 300 mg CBA (<span class=3D"ref-callout-list"><a class=3D"ref=
-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-30710469','le=
xi-content-ref-28011614']" aria-label=3D"list of references">Ref</a></span>=
).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Maintenanc=
e dose: <b>IV:</b></p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Dialysis d=
ays: 180 mg CBA on dialysis days (administer after dialysis) (<span class=
=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-i=
d=3D"['lexi-content-ref-30710469','lexi-content-ref-28011614','lexi-content=
-ref-Expert.DOR']" aria-label=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Nondialysi=
s days: 130 mg CBA on nondialysis days (<span class=3D"ref-callout-list"><a=
 class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-=
30710469','lexi-content-ref-28011614']" aria-label=3D"list of references">R=
ef</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Peritoneal dialysis:</b>
                     <b>IV:</b> Loading dose: 300 mg CBA followed by 150 to=
 200 mg CBA once daily as maintenance starting 24 hours after the loading d=
ose (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" le=
xi-content-ref-id=3D"['lexi-content-ref-24189256']" aria-label=3D"list of r=
eferences">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>CRRT:</b> Drug clearance is dependent on the efflue=
nt flow rate, filter type, and method of renal replacement. Recommendations=
 are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg=
/hour (or ~1,500 to 3,000 mL/hour), and minimal residual kidney function un=
less otherwise noted. Appropriate dosing requires consideration of adequate=
 drug concentrations (eg, site of infection) and consideration of initial l=
oading doses. Close monitoring of response and adverse reactions due to dru=
g accumulation is important.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <b> IV:</b> Loading dose: 300 mg CBA followed by 220 m=
g CBA every 12 hours as maintenance starting 12 hours after the loading dos=
e (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi=
-content-ref-id=3D"['lexi-content-ref-30710469']" aria-label=3D"list of ref=
erences">Ref</a></span>). <b>Note:</b> The pro-drug CMS is removed by CRRT =
(~10% per hour), therefore patients receiving CRRT require higher daily dos=
es than patients with normal kidney function (<span class=3D"ref-callout-li=
st"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-conten=
t-ref-30710469','lexi-content-ref-27474468','lexi-content-ref-23147733']" a=
ria-label=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>PIRRT (eg, sustained, low-efficiency diafiltration)=
: </b>Drug clearance is dependent on the effluent flow rate, filter type, a=
nd method of renal replacement. Appropriate dosing requires consideration o=
f adequate drug concentrations (eg, site of infection) and consideration of=
 initial loading doses. Close monitoring of response and adverse reactions =
due to drug accumulation is important.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <b>IV:</b> Loading dose: 300 mg CBA followed by mainte=
nance dose based on kidney function and duration of PIRRT session. Add 10% =
per 1 hour of PIRRT replacement to the recommended baseline daily dose for =
kidney function (eg, CrCl &lt;5 mL/minute, 130 mg CBA/day); administer in 2=
 divided doses 12 hours apart starting 12 hours after the loading dose (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-30710469','lexi-content-ref-28011614']" ari=
a-label=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">For exampl=
e, in a patient with a CrCl of &lt;5 mL/minute receiving 10 hours nocturnal=
 PIRRT session each day, the suggested CBA maintenance dose is: 130 mg + (1=
0 hours =C3=97 13) =3D 260 mg CBA/day, administered as 130 mg every 12 hour=
s. PIRRT session should begin 1 to 2 hours after the afternoon/evening dose=
 (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-=
content-ref-id=3D"['lexi-content-ref-30710469','lexi-content-ref-28011614']=
" aria-label=3D"list of references">Ref</a></span>).</p></div>
<div id=3D"F50989164" class=3D"block doha drugH1Div"><span class=3D"drugH1"=
>Dosing: Hepatic Impairment: Adult</span>
                  <p style=3D"text-indent:0em;display:inline">There are no =
dosage adjustments provided in the manufacturer=E2=80=99s labeling.</p></di=
v>
<div id=3D"F18881845" class=3D"block dot drugH1Div"><span class=3D"drugH1">=
Dosing: Adjustment for Toxicity: Adult</span>
                  <p style=3D"text-indent:-2em;margin-left:2em;text-align:j=
ustify;">CNS toxicity: Dose reduction may reduce neurologic symptoms.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;text-align:j=
ustify;">Nephrotoxicity: Withhold treatment if signs of renal impairment oc=
cur during treatment.</p></div>
<div id=3D"F154562" class=3D"block doe drugH1Div"><span class=3D"drugH1">Do=
sing: Older Adult</span>
                  <p style=3D"text-indent:0em;display:inline">Refer to adul=
t dosing.</p></div>
<div id=3D"F154569" class=3D"block dop drugH1Div"><span class=3D"drugH1">Do=
sing: Pediatric</span><p>(For additional information <a data-topicid=3D"131=
61" class=3D"drug drug_pediatric" rel=3D"external" href=3D"https://medilib.=
ir/uptodate/show/13161">see "Colistin (colistimethate): Pediatric drug info=
rmation"</a>)</p>
                  <p style=3D"text-indent:0em;display:inline">
                     <b>Note:</b> Due to risk of toxicity and efficacy limi=
tations, systemic use is limited to when less toxic alternatives are not ef=
fective or not tolerated. When used, typically recommended as part of combi=
nation therapy (<span class=3D"ref-callout-list"><a class=3D"ref-callout-li=
st-link" lexi-content-ref-id=3D"['lexi-content-ref-31844014','lexi-content-=
ref-31872226','lexi-content-ref-30710469','lexi-content-ref-34864936','lexi=
-content-ref-35439291']" aria-label=3D"list of references">Ref</a></span>).=
 Doses should be based on ideal body weight in obese patients; dosage prima=
rily expressed in terms of colistin base activity (CBA). <b>CBA 1 mg</b> is=
 defined to be equivalent to<b> colistimethate sodium (CMS) 30,000 units, w=
hich is equivalent to ~2.4 mg CMS</b> (<span class=3D"ref-callout-list"><a =
class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-E=
MA.1','lexi-content-ref-30710469','lexi-content-ref-16723606','lexi-content=
-ref-23728146','lexi-content-ref-28011614']" aria-label=3D"list of referenc=
es">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>General dosing:</b> Infants, Children, and Adolesce=
nts: IM, IV: 2.5 to 5 mg CBA/kg/<b>day</b> divided every 6 to 12 hours (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-AAP.1','lexi-content-ref-Manu.1']" aria-lab=
el=3D"list of references">Ref</a></span>). Higher doses may be necessary in=
 some instances; see dosing for specific indications.</p>
                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"ad1a4b51-9af0-4598-86b2-cc=
608abe0f14" class=3D"collapsible-indication-title">CNS infection, multidrug=
 resistant</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>CNS infection (VP-shunt infection, ventriculi=
tis, meningitis), multidrug resistant:</b> Variable doses reported; optimal=
 dose not defined.</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">Infa=
nts and Children: Very limited data available: Intraventricular/Intrathecal=
: Reported range: 1 to 4.2 mg CBA/dose once daily in combination with syste=
mic antibiotics (<span class=3D"ref-callout-list"><a class=3D"ref-callout-l=
ist-link" lexi-content-ref-id=3D"['lexi-content-ref-19460268','lexi-content=
-ref-34013828','lexi-content-ref-28203777','lexi-content-ref-16916866','lex=
i-content-ref-20358244']" aria-label=3D"list of references">Ref</a></span>)=
. Doses should be individualized based on culture/susceptibility, minimum i=
nhibitory concentration (MIC), and tolerability, with consideration of pati=
ent size and cerebrospinal fluid volume. Case reports in patients 2 months =
to 4 years of age have described a titration regimen in which 1 mg CBA is a=
dministered on day 1, followed by 2 mg CBA once daily for 1 to 2 days, then=
 4 mg CBA once daily thereafter for a total of 8 to 18 days of therapy (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-34955517','lexi-content-ref-19460268','lexi=
-content-ref-34013828','lexi-content-ref-16916866']" aria-label=3D"list of =
references">Ref</a></span>). In other case reports, patients aged 1 month t=
o 5 years received intrathecal or intraventricular colistin without titrati=
on at a dose of 4.2 mg CBA once daily for 5 to 9 days (<span class=3D"ref-c=
allout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['le=
xi-content-ref-20119725','lexi-content-ref-20358244']" aria-label=3D"list o=
f references">Ref</a></span>). Doses as high as 10 mg CBA (after titration)=
 have been reported to treat multidrug-resistant <i>Acinetobacter baumannii=
</i> in an infant (<span class=3D"ref-callout-list"><a class=3D"ref-callout=
-list-link" lexi-content-ref-id=3D"['lexi-content-ref-19460268']" aria-labe=
l=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">Adol=
escents: Very limited data available: Intraventricular/Intrathecal: 4.2 mg =
CBA/day (equivalent to 10 mg <b>CMS</b>/day) (<span class=3D"ref-callout-li=
st"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-conten=
t-ref-33575996','lexi-content-ref-28203777','lexi-content-ref-34013828','le=
xi-content-ref-29743769','lexi-content-ref-34497678','lexi-content-ref-1721=
4907']" aria-label=3D"list of references">Ref</a></span>). Reported range: =
2 to 8.3 mg CBA/day in 1 or 2 divided doses; duration of 10 to 14 days most=
 commonly reported; however, use for up to 24 days has been described; most=
 commonly administered in a single daily dose (<span class=3D"ref-callout-l=
ist"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-conte=
nt-ref-33575996','lexi-content-ref-24728736','lexi-content-ref-34013828','l=
exi-content-ref-10825065','lexi-content-ref-23201321']" aria-label=3D"list =
of references">Ref</a></span>). In some reports, the dose was titrated up f=
rom 2.1 mg CBA once daily to 4.2 mg CBA once daily (<span class=3D"ref-call=
out-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-=
content-ref-34013828','lexi-content-ref-17214907']" aria-label=3D"list of r=
eferences">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"cc30ca9c-db9e-4f82-ad38-00=
cf0b11a720" class=3D"collapsible-indication-title">Cystic fibrosis, pulmona=
ry infection</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Cystic fibrosis, pulmonary infection:</b> Lim=
ited data available:</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">IV: =
Acute pulmonary exacerbation: Children =E2=89=A55 years and Adolescents: IV=
: Usual reported range: 3 to 5 mg CBA/kg/day divided every 8 hours; maximum=
 dose: 100 mg CBA/dose (<span class=3D"ref-callout-list"><a class=3D"ref-ca=
llout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-1763528','lexi-c=
ontent-ref-11402633','lexi-content-ref-22949160']" aria-label=3D"list of re=
ferences">Ref</a></span>); doses &gt;5 mg CBA/kg/day (up to 8 mg CBA/kg/day=
) have been described; however, higher doses are associated with more sever=
e toxicity (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-l=
ink" lexi-content-ref-id=3D"['lexi-content-ref-1763528','lexi-content-ref-1=
1402633']" aria-label=3D"list of references">Ref</a></span>). Treatment dur=
ation varies and is dependent on patient-specific factors, including respon=
se to therapy; typical duration is 10 to 21 days (<span class=3D"ref-callou=
t-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-co=
ntent-ref-31487382','lexi-content-ref-34588142','lexi-content-ref-27139161'=
]" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">Inha=
led: Children and Adolescents: Inhalation: Usual dose: 75 to 150 mg CBA via=
 nebulizer every 12 hours; reported range: 33 to 150 mg CBA/dose; administr=
ation of doses =E2=89=A466 mg has been reported as frequently as every 8 ho=
urs. Duration depends on specific use (eg, maintenance therapy vs eradicati=
on therapy) and should be individualized (<span class=3D"ref-callout-list">=
<a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-re=
f-28614995','lexi-content-ref-12358344','lexi-content-ref-34806975','lexi-c=
ontent-ref-20500046','lexi-content-ref-22762867','lexi-content-ref-27576543=
','lexi-content-ref-22379071','lexi-content-ref-20729233','lexi-content-ref=
-Waters.1']" aria-label=3D"list of references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"08e33a60-0755-408b-bb33-2c=
f5e44040f1" class=3D"collapsible-indication-title">Pulmonary infection due =
to multidrug-resistant gram-negative bacilli</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Pulmonary infection due to multidrug-resistan=
t gram-negative bacilli (eg, <i>P. aeruginosa, Acinetobacter</i> spp):</b> =
Limited data available: <b>Note: </b>Use in combination with systemic thera=
py (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lex=
i-content-ref-id=3D"['lexi-content-ref-30710469','lexi-content-ref-25939411=
']" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">Infa=
nts: Inhalation: 4 mg/kg/dose via nebulizer every 12 hours; maximum dose: 7=
5 mg/dose (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-li=
nk" lexi-content-ref-id=3D"['lexi-content-ref-25939411']" aria-label=3D"lis=
t of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">Chil=
dren and Adolescents: Inhalation: 75 to 150 mg CBA via nebulizer every 12 h=
ours (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" l=
exi-content-ref-id=3D"['lexi-content-ref-20500046','lexi-content-ref-259394=
11','lexi-content-ref-24673698']" aria-label=3D"list of references">Ref</a>=
</span>); reported range: 30 to 150 mg CBA/dose every 12 hours (<span class=
=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-i=
d=3D"['lexi-content-ref-33713930','lexi-content-ref-20658485','lexi-content=
-ref-20500046','lexi-content-ref-25939411','lexi-content-ref-24673698']" ar=
ia-label=3D"list of references">Ref</a></span>).</p></div>
</div>

                  <div class=3D"collapsible-indication">
                     <span data-indication-id=3D"2d64f970-a7e6-463a-ac54-a6=
31497c7616" class=3D"collapsible-indication-title">Systemic infections, due=
 to multidrug-resistant gram-negative bacilli</span>
                     <div class=3D"collapsible-indication-wrap">
                        <p style=3D"text-indent:-2em;margin-left:2em;">
                           <b>Systemic infections (eg, bacteremia, pneumoni=
a) due to multidrug-</b>
                           <b>resistant gram-negative bacilli (alternative =
agent):</b></p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">
                           <b>Note: </b>Typically recommended as part of an=
 appropriate combination regimen. Polymyxin B may be preferred over colisti=
n, except for treatment of cystitis (<span class=3D"ref-callout-list"><a cl=
ass=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-318=
44014','lexi-content-ref-31872226','lexi-content-ref-34864936','lexi-conten=
t-ref-35439291']" aria-label=3D"list of references">Ref</a></span>).</p>
                        <p style=3D"text-indent:-2em;margin-left:4em;">Infa=
nts, Children, and Adolescents: IM, IV: Loading dose of 2.5 to 5 mg CBA/kg =
once (maximum dose: 300 mg CBA/dose), followed by 5 mg CBA/kg/day divided e=
very 8 to every 12 hours (maximum dose: 180 mg/dose) (<span class=3D"ref-ca=
llout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lex=
i-content-ref-31844014','lexi-content-ref-31872226','lexi-content-ref-24501=
388','lexi-content-ref-29361414','lexi-content-ref-22935871','lexi-content-=
ref-32179149']" aria-label=3D"list of references">Ref</a></span>). Populati=
on pharmacokinetic studies have suggested that higher doses may be necessar=
y to treat severe/critical illness; doses of ~10 mg CBA/kg/day in divided d=
oses have been described; monitor closely for toxicity (<span class=3D"ref-=
callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['l=
exi-content-ref-33782000','lexi-content-ref-35349496','lexi-content-ref-327=
73667','lexi-content-ref-30722017']" aria-label=3D"list of references">Ref<=
/a></span>).</p></div>
</div>

                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Dosage adjustment for concomitant therapy:</b> Sign=
ificant drug interactions exist, requiring dose/frequency adjustment or avo=
idance. Consult drug interactions database for more information.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>Dosing adjustment for toxicity</b>: Infants, Childr=
en, and Adolescents: Based on experience with other aminoglycosides, the fo=
llowing should be considered: <b></b></p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">CNS toxici=
ty: Dose reduction may reduce neurologic symptoms.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Nephrotoxi=
city: Withhold treatment if signs of renal impairment occur during treatmen=
t.</p></div>
<div id=3D"F51108502" class=3D"block dorp drugH1Div"><span class=3D"drugH1"=
>Dosing: Kidney Impairment: Pediatric</span>
                  <p style=3D"text-indent:0em;display:inline">There are no =
pediatric specific recommendations in the manufacturer=E2=80=99s labeling; =
in adult patients, dosage adjustment is suggested.</p></div>
<div id=3D"F51090201" class=3D"block dohp drugH1Div"><span class=3D"drugH1"=
>Dosing: Hepatic Impairment: Pediatric</span>
                  <p style=3D"text-indent:0em;display:inline">There are no =
dosage adjustments provided in the manufacturer=E2=80=99s labeling.</p></di=
v>
<div id=3D"F154539" class=3D"block adr drugH1Div"><span class=3D"drugH1">Ad=
verse Reactions</span>
                  <p style=3D"text-indent:0em;display:inline">The following=
 adverse drug reactions and incidences are derived from product labeling un=
less otherwise specified.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">&gt;10%:</=
p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Genitourin=
ary: Nephrotoxicity (18% to 26% [Dalfino 2012; Oliveira 2009])</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Renal: Acu=
te renal failure (33% to 60% [Akajagbor 2013; Deryke 2010])</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">1% to 10%:=
</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Central ne=
rvous system: Neurotoxicity (7%; higher incidence with high-dose IV use in =
cystic fibrosis [Bosso 1991; Koch-Weser 1970])</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Frequency =
not defined:</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Central ne=
rvous system: Dizziness, oral paresthesia, paresthesia, peripheral paresthe=
sia, seizures, slurred speech, vertigo</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Dermatolog=
ic: Pruritus, skin rash, urticaria</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Gastrointe=
stinal: <i>Clostridioides difficile</i>-associated diarrhea, gastric distre=
ss</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Genitourin=
ary: Decreased urine output</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Hypersensi=
tivity: Anaphylaxis</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Renal: Dec=
reased creatinine clearance, increased blood urea nitrogen, increased serum=
 creatinine</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Respirator=
y: Apnea, respiratory distress</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Miscellane=
ous: Fever</p></div>
<div id=3D"F154549" class=3D"block coi drugH1Div"><span class=3D"drugH1">Co=
ntraindications</span>
                  <p style=3D"text-indent:0em;display:inline">Hypersensitiv=
ity to colistimethate, colistin, or any component of the formulation.</p></=
div>
<div id=3D"F154536" class=3D"block war drugH1Div"><span class=3D"drugH1">Wa=
rnings/Precautions</span>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Concerns related to adverse effects:</i></b></p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Bronchoconstriction: Use of inhaled colistimethate (off-label route) may re=
sult in bronchoconstriction. Use with caution in patients with hyperactive =
airways; consider administration of a bronchodilator (eg, albuterol) within=
 15 minutes prior to administration (Le 2010).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
CNS toxicity: Transient, reversible neurological disturbances (eg, dizzines=
s, numbness, paresthesia, generalized pruritus, slurred speech, tingling, v=
ertigo) may occur. Patients must be cautioned about performing tasks which =
require mental alertness (eg, operating machinery or driving). Dose reducti=
on may reduce neurologic symptoms.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Renal toxicity: Dose-dependent nephrotoxicity has been reported, generally =
reversible upon discontinuation of treatment.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Respiratory arrest: Respiratory arrest has been reported with use; impaired=
 renal function may increase the risk for neuromuscular blockade and apnea.=
</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Superinfection: Prolonged use may result in fungal or bacterial superinfect=
ion, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomem=
branous colitis; CDAD has been observed &gt;2 months postantibiotic treatme=
nt.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Disease-related concerns:</i></b></p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Renal impairment: Use with caution in patients with preexisting renal impai=
rment; dosage adjustments are recommended. Impaired renal function may incr=
ease the risk for respiratory arrest.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">
                     <b>
                        <i>Other warnings/precautions:</i></b></p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Appropriate use: Inhalation (off-label route): Once mixed, colistimethate b=
egins conversion to bioactive colistin, a component of which may result in =
severe pulmonary toxicity (Le 2010). Solutions for inhalation must be mixed=
 immediately prior to administration and used within 24 hours to reduce the=
 incidence of pulmonary toxicity.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">=E2=80=A2 =
Safety: Potential for dosing errors due to lack of standardization in liter=
ature when referring to product and dose. Colistimethate (inactive prodrug)=
 and colistin base strengths are not interchangeable; verify prescribed dos=
e is expressed in terms of colistin base activity prior to dispensing.</p><=
/div>
<div id=3D"F52878398" class=3D"block add-pediatric-warn-info drugH1Div"><sp=
an class=3D"drugH1">Warnings: Additional Pediatric Considerations</span>
                  <p style=3D"text-indent:0em;display:inline">Electrolyte d=
isturbances, including hypomagnesemia, hypokalemia, hypocalcemia, and hypon=
atremia, have been described in neonates receiving IV colistimethate and ma=
y require supplementation. Disturbances have been reported mostly in popula=
tions mainly comprised of preterm patients, and risk may be higher in the v=
ery low-birth-weight population (weighing &lt;1,500 g at birth); monitor el=
ectrolytes closely during therapy (Aksoy 2020; Alan 2014; Ambreen 2020; Ant=
achopoulos 2017; Ilhan 2018; =C4=B0pek 2017). Electrolyte disturbances may =
be mediated by renal tubulopathy and associated with other manifestations o=
f kidney toxicity (Thomas 2019; Yurttutan 2021).</p>
                  <p style=3D"text-indent:0em;margin-top:2em;">Neurotoxicit=
y, which may occur in all ages, may present differently in the neonatal pop=
ulation compared to older pediatric patients; in term or preterm neonates, =
neurotoxicity may present as apnea or seizures; monitor closely (Alan 2014;=
 Ambreen 2020; =C3=87a=C4=9Fan 2017; Nakwan 2019).</p></div>
<div id=3D"F154544" class=3D"block foc drugH1Div"><span class=3D"drugH1">Do=
sage Forms: US</span>
                  <p style=3D"text-indent:0em;text-align:justify;display:in=
line">Excipient information presented when available (limited, particularly=
 for generics); consult specific product labeling.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;text-align:j=
ustify;">Solution Reconstituted, Injection [preservative free]: </p>
                  <p style=3D"text-indent:-2em;margin-left:4em;text-align:j=
ustify;">Coly-Mycin M: 150 mg (1 ea)</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;text-align:j=
ustify;">Generic: 150 mg (1 ea)</p></div>
<div id=3D"F154532" class=3D"block geq drugH1Div"><span class=3D"drugH1">Ge=
neric Equivalent Available: US</span>
                  <p style=3D"text-indent:0em;display:inline">Yes</p></div>
<div id=3D"F16323078" class=3D"block fee drugH1Div"><span class=3D"drugH1">=
Pricing: US</span>
                  <p style=3D"text-indent:-2em;margin-left:2em;text-align:j=
ustify;">
                     <b>Solution (reconstituted)</b> (Colistimethate Sodium=
 (CBA) Injection)</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;text-align:j=
ustify;">150 mg (per each): $12.42 - $35.00</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;text-align:j=
ustify;">
                     <b>Solution (reconstituted)</b> (Coly-Mycin M Injectio=
n)</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;text-align:j=
ustify;">150 mg (per each): $33.60</p>
                  <p style=3D"text-indent:0em;">
                     <b>Disclaimer: </b>A representative AWP (Average Whole=
sale Price) price or price range is provided as reference price only. A ran=
ge is provided when more than one manufacturer's AWP price is available and=
 uses the low and high price reported by the manufacturers to determine the=
 range. The pricing data should be used for benchmarking purposes only, and=
 as such should not be used alone to set or adjudicate any prices for reimb=
ursement or purchasing functions or considered to be an exact price for a s=
ingle product and/or manufacturer.  Medi-Span expressly disclaims all warra=
nties of any kind or nature, whether express or implied, and assumes no lia=
bility with respect to accuracy of price or price range data published in i=
ts solutions.  In no event shall Medi-Span be liable for special, indirect,=
 incidental, or consequential damages arising from use of price or price ra=
nge data.  Pricing data is updated monthly.</p></div>
<div id=3D"F52866438" class=3D"block dinfoc drugH1Div"><span class=3D"drugH=
1">Dosage Forms: Canada</span>
                  <p style=3D"text-indent:0em;text-align:justify;display:in=
line">Excipient information presented when available (limited, particularly=
 for generics); consult specific product labeling.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;text-align:j=
ustify;">Solution Reconstituted, Injection: </p>
                  <p style=3D"text-indent:-2em;margin-left:4em;text-align:j=
ustify;">Coly-Mycin M: 150 mg (1 ea)</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;text-align:j=
ustify;">Generic: 150 mg (1 ea)</p></div>
<div id=3D"F154546" class=3D"block adm drugH1Div"><span class=3D"drugH1">Ad=
ministration: Adult</span>
                  <p style=3D"text-indent:-2em;margin-left:2em;">IV: Infuse=
 over 30 minutes to 1 hour (<span class=3D"ref-callout-list"><a class=3D"re=
f-callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-30710469']" =
aria-label=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Inhalation=
 (off-label route): Administer solution via nebulizer (vibrating plate nebu=
lizer may be preferred (<span class=3D"ref-callout-list"><a class=3D"ref-ca=
llout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-23132092']" aria=
-label=3D"list of references">Ref</a></span>)) promptly following preparati=
on to decrease possibility of high concentrations of colistin from forming =
which may lead to potentially life-threatening lung toxicity. Consider use =
of a bronchodilator (eg, albuterol) within 15 minutes prior to administrati=
on (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lex=
i-content-ref-id=3D"['lexi-content-ref-20500046']" aria-label=3D"list of re=
ferences">Ref</a></span>). If patient is on a ventilator, place medicine in=
 a T-piece at the midinspiratory circuit of the ventilator. One study in ad=
ult patients with VAP administered colistimethate over 60 minutes using a v=
ibrating plate nebulizer positioned on the inspiratory limb 10 cm proximal =
to the Y-piece (<span class=3D"ref-callout-list"><a class=3D"ref-callout-li=
st-link" lexi-content-ref-id=3D"['lexi-content-ref-23132092']" aria-label=
=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <b>Note:</b> A case report of fatal lung toxicity impl=
icated <i>in vitro</i> colistin formation from an inhalation solution as a =
potential etiology, but data regarding the concentration, formulation and s=
torage of the inhaled colistin administered to the patient were not reporte=
d (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi=
-content-ref-id=3D"['lexi-content-ref-FDA.1','lexi-content-ref-18046039','l=
exi-content-ref-18606838']" aria-label=3D"list of references">Ref</a></span=
>). An acceptable limit of in vitro colistin formation to prevent potential=
 toxicity is unknown. Limited stability data are available regarding the st=
orage of colistin solution for inhaled administration (<span class=3D"ref-c=
allout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['le=
xi-content-ref-23070159','lexi-content-ref-18606838']" aria-label=3D"list o=
f references">Ref</a></span>). Storing for &gt;24 hours may increase the ri=
sk for potential lung toxicity; preparation immediately prior to administra=
tion is recommended (<span class=3D"ref-callout-list"><a class=3D"ref-callo=
ut-list-link" lexi-content-ref-id=3D"['lexi-content-ref-FDA.1','lexi-conten=
t-ref-20500046','lexi-content-ref-18606838']" aria-label=3D"list of referen=
ces">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Intratheca=
l/intraventricular (off-label route): Administer only preservative-free sol=
utions via intrathecal/intraventricular routes. Administer promptly after p=
reparation. Discard unused portion of vial. When administered through a ven=
tricular drain, clamp drain for 15 to 60 minutes before opening the drain t=
o allow colistimethate solution to equilibrate in the CSF (<span class=3D"r=
ef-callout-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"=
['lexi-content-ref-15494903','lexi-content-ref-28203777']" aria-label=3D"li=
st of references">Ref</a></span>).</p></div>
<div id=3D"F52612455" class=3D"block admp drugH1Div"><span class=3D"drugH1"=
>Administration: Pediatric</span>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Parenteral=
:</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">IM: Admini=
ster deep into a large muscle mass (eg, gluteal muscle or lateral part of t=
he thigh).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">IV push: A=
dminister over 3 to 5 minutes.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Intermitte=
nt IV infusion: Administer over 20 to 60 minutes; most commonly infused ove=
r 30 minutes in neonates (<span class=3D"ref-callout-list"><a class=3D"ref-=
callout-list-link" lexi-content-ref-id=3D"['lexi-content-ref-33782000','lex=
i-content-ref-35349496','lexi-content-ref-32892635','lexi-content-ref-30073=
562','lexi-content-ref-23689704','lexi-content-ref-27276179']" aria-label=
=3D"list of references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Inhalation=
: Administer solution via nebulizer promptly following preparation of solut=
ion to decrease possibility of high concentrations of colistin from forming=
, which may lead to potentially life-threatening lung toxicity. Consider us=
e of a bronchodilator (eg, albuterol) within 15 minutes prior to administra=
tion (<span class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" l=
exi-content-ref-id=3D"['lexi-content-ref-20500046']" aria-label=3D"list of =
references">Ref</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <b>Note:</b> A case report of fatal lung toxicity impl=
icated in vitro colistin formation from an inhalation solution as a potenti=
al etiology, but data regarding the concentration, formulation, and storage=
 of the inhaled colistin administered to the patient were not reported (<sp=
an class=3D"ref-callout-list"><a class=3D"ref-callout-list-link" lexi-conte=
nt-ref-id=3D"['lexi-content-ref-FDA.1','lexi-content-ref-18046039','lexi-co=
ntent-ref-18606838']" aria-label=3D"list of references">Ref</a></span>). An=
 acceptable limit of in vitro colistin formation to prevent potential toxic=
ity is unknown. Limited stability data are available regarding the storage =
of colistin solution for inhaled administration (<span class=3D"ref-callout=
-list"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-con=
tent-ref-23070159','lexi-content-ref-18606838']" aria-label=3D"list of refe=
rences">Ref</a></span>). Storing for &gt;24 hours may increase the risk for=
 potential lung toxicity; preparation immediately prior to administration i=
s recommended (<span class=3D"ref-callout-list"><a class=3D"ref-callout-lis=
t-link" lexi-content-ref-id=3D"['lexi-content-ref-FDA.1','lexi-content-ref-=
20500046','lexi-content-ref-18606838']" aria-label=3D"list of references">R=
ef</a></span>).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Intraventr=
icular/Intrathecal: Administer only preservative-free solutions via intrath=
ecal/intraventricular routes. Administer promptly after preparation. Discar=
d unused portion of vial. When administering via a ventricular drain, clamp=
 the drain for 15 to 60 minutes to allow equilibration of colistin with cer=
ebrospinal fluid prior to opening the drain (<span class=3D"ref-callout-lis=
t"><a class=3D"ref-callout-list-link" lexi-content-ref-id=3D"['lexi-content=
-ref-28841583','lexi-content-ref-19892577','lexi-content-ref-19460268','lex=
i-content-ref-34013828','lexi-content-ref-28203777','lexi-content-ref-16916=
866','lexi-content-ref-34497678']" aria-label=3D"list of references">Ref</a=
></span>).</p></div>
<div id=3D"F154545" class=3D"block use drugH1Div"><span class=3D"drugH1">Us=
e: Labeled Indications</span>
                  <p style=3D"text-indent:0em;display:inline">Treatment of =
acute or chronic infections due to sensitive strains of certain gram-negati=
ve bacilli, including <i>Pseudomonas aeruginosa</i>, <i>Enterobacter aeroge=
nes, Escherichia coli</i>, and <i>Klebsiella pneumoniae</i>, that are resis=
tant to other antibiotics or in patients who are unable to take other antib=
iotics.</p></div>
<div id=3D"F25475254" class=3D"block off-label drugH1Div"><span class=3D"dr=
ugH1">Use: Off-Label: Adult</span><p>Bronchiectasis, exacerbation preventio=
n; Cystic fibrosis; Meningitis, bacterial; Pneumonia, hospital-acquired or =
ventilator-associated</p></div>
<div id=3D"F14219656" class=3D"block mst drugH1Div"><span class=3D"drugH1">=
Medication Safety Issues</span>
                  <div class=3D"collapsible">
                     <span class=3D"collapsible-title">High alert medicatio=
n:</span>
                     <div class=3D"collapsible-wrap">
                        <p style=3D"text-indent:-2em;margin-left:4em;">The =
Institute for Safe Medication Practices (ISMP) includes this medication (in=
trathecal administration) among its list of drugs that have a heightened ri=
sk of causing significant patient harm when used in error.</p></div>
</div>

                  <div class=3D"collapsible">
                     <span class=3D"collapsible-title">Other safety concern=
s:</span>
                     <div class=3D"collapsible-wrap">
                        <p style=3D"text-indent:-2em;margin-left:4em;">Due =
to the potential for dosing errors, it is recommended that prescriptions fo=
r colistimethate be expressed as mg of colistin base activity only.</p></di=
v>
</div>
</div>
<div id=3D"F13299084" class=3D"block cyt drugH1Div"><span class=3D"drugH1">=
Metabolism/Transport Effects</span>
                  <p style=3D"text-indent:0em;display:inline">None known.</=
p></div>
<div id=3D"F154540" class=3D"block dri drugH1Div"><span class=3D"drugH1">Dr=
ug Interactions</span><br><br><div class=3D"clear"></div><p xmlns=3D""></p>=
<div xmlns=3D"" class=3D"inner"><p style=3D"text-indent:0em;display:inline"=
><b>Note</b>: Interacting drugs may <b>not be individually listed below</b>=
 if they are part of a group interaction (eg, individual drugs within =E2=
=80=9CCYP3A4 Inducers [Strong]=E2=80=9D are NOT listed).  For a complete li=
st of drug interactions by individual drug name and detailed management rec=
ommendations, use the Lexicomp drug interactions program by clicking on the=
 =E2=80=9CLaunch drug interactions program=E2=80=9D link above.</p><p xmlns=
=3D""></p></div>

                  <p style=3D"text-indent:-2em;margin-left:2em;">Aminoglyco=
sides: May enhance the nephrotoxic effect of Colistimethate. Aminoglycoside=
s may enhance the neuromuscular-blocking effect of Colistimethate. Manageme=
nt: Avoid coadministration of colistimethate and aminoglycosides whenever p=
ossible due to the risk of nephrotoxicity and neuromuscular blockade. If co=
administration cannot be avoided, monitor renal and neuromuscular function.=
<i> Risk D: Consider therapy modification</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Amphoteric=
in B: May enhance the nephrotoxic effect of Colistimethate. Management: Avo=
id coadministration of colistimethate and amphotericin B whenever possible =
due to the potential for additive or synergistic nephrotoxicity. If coadmin=
istration cannot be avoided, closely monitor renal function.<i> Risk D: Con=
sider therapy modification</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Bacillus c=
lausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii=
.  Management: Bacillus clausii should be taken in between antibiotic doses=
 during concomitant therapy.<i> Risk D: Consider therapy modification</i></=
p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Bacitracin=
 (Systemic): Colistimethate may enhance the nephrotoxic effect of Bacitraci=
n (Systemic). <i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">BCG (Intra=
vesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesi=
cal). <i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">BCG Vaccin=
e (Immunization): Antibiotics may diminish the therapeutic effect of BCG Va=
ccine (Immunization). <i> Risk C: Monitor therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Capreomyci=
n: May enhance the neuromuscular-blocking effect of Colistimethate.<i> Risk=
 C: Monitor therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Cefaloridi=
ne [Cephaloridine]: Colistimethate may enhance the nephrotoxic effect of Ce=
faloridine [Cephaloridine]. <i> Risk C: Monitor therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Cefazedone=
: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor =
therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Cephalothi=
n: May enhance the nephrotoxic effect of Colistimethate.<i> Risk C: Monitor=
 therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Cholera Va=
ccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. =
 Management: Avoid cholera vaccine in patients receiving systemic antibioti=
cs, and within 14 days following the use of oral or parenteral antibiotics.=
<i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Fecal Micr=
obiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i=
> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Fecal Micr=
obiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of =
Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Immune Che=
ckpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics m=
ay diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD=
-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Lactobacil=
lus and Estriol: Antibiotics may diminish the therapeutic effect of Lactoba=
cillus and Estriol. <i> Risk C: Monitor therapy</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Mecamylami=
ne: Colistimethate may enhance the neuromuscular-blocking effect of Mecamyl=
amine. <i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Methoxyflu=
rane: Colistimethate may enhance the nephrotoxic effect of Methoxyflurane. =
<i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Netilmicin=
 (Ophthalmic): Colistimethate may enhance the nephrotoxic effect of Netilmi=
cin (Ophthalmic). <i> Risk X: Avoid combination</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Neuromuscu=
lar-Blocking Agents: Colistimethate may enhance the neuromuscular-blocking =
effect of Neuromuscular-Blocking Agents.  Management: If possible, avoid co=
ncomitant use of these products. Monitor for deeper, prolonged neuromuscula=
r-blocking effects (respiratory paralysis) in patients receiving concomitan=
t neuromuscular-blocking agents and colistimethate.<i> Risk D: Consider the=
rapy modification</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Polymyxin =
B: Colistimethate may enhance the nephrotoxic effect of Polymyxin B. Polymy=
xin B may enhance the neuromuscular-blocking effect of Colistimethate. Coli=
stimethate may enhance the neurotoxic effect of Polymyxin B.  Management: C=
oadministration of polymyxin B and other potentially neurotoxic or nephroto=
xic agents, such as colistimethate, is generally not recommended. If this c=
ombination must be used, monitor carefully for enhanced neurotoxic and neph=
rotoxic effects.<i> Risk D: Consider therapy modification</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Sodium Pic=
osulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosul=
fate.  Management: Consider using an alternative product for bowel cleansin=
g prior to a colonoscopy in patients who have recently used or are concurre=
ntly using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Typhoid Va=
ccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. =
Only the live attenuated Ty21a strain is affected.  Management: Avoid use o=
f live attenuated typhoid vaccine (Ty21a)  in patients being treated with s=
ystemic antibacterial agents. Postpone vaccination until 3 days after cessa=
tion of antibiotics and avoid starting antibiotics within 3 days of last va=
ccine dose.<i> Risk D: Consider therapy modification</i></p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Vancomycin=
: May enhance the nephrotoxic effect of Colistimethate. Management: Avoid c=
oadministration of colistimethate and vancomycin whenever possible due to t=
he potential for additive or synergistic nephrotoxicity. If coadministratio=
n cannot be avoided, closely monitor renal function.<i> Risk D: Consider th=
erapy modification</i></p></div>
<div id=3D"F5105300" class=3D"block pri drugH1Div"><span class=3D"drugH1">P=
regnancy Considerations</span>
                  <p style=3D"text-indent:0em;display:inline">Adverse event=
s have been observed in animal reproduction studies. Colistimethate crosses=
 the placenta in humans.</p></div>
<div id=3D"F5105303" class=3D"block brc drugH1Div"><span class=3D"drugH1">B=
reastfeeding Considerations</span>
                  <p style=3D"text-indent:0em;display:inline">Colistin (the=
 active form of colistimethate sodium) and colistin sulphate (another form =
of colistin) are excreted in human milk. The manufacturer recommends cautio=
n if giving colistimethate sodium to a breast-feeding woman. Nondose-relate=
d effects could include modification of bowel flora. </p></div>
<div id=3D"F5105494" class=3D"block mop drugH1Div"><span class=3D"drugH1">M=
onitoring Parameters</span>
                  <p style=3D"text-indent:0em;display:inline">Serum creatin=
ine, BUN; urine output; signs of neurotoxicity; signs of bronchospasm (inha=
lation [off-label route]); colistin serum concentrations (to ensure adequat=
e drug exposure particularly early in therapy) (ESCMID/EUCAST [Tsuji 2019])=
.</p></div>
<div id=3D"F53623768" class=3D"block rer drugH1Div"><span class=3D"drugH1">=
Reference Range</span>
                  <p style=3D"text-indent:0em;display:inline">Target serum =
concentration is 2 mg/L for susceptible organisms (irrespective of reported=
 MIC) (ESCMID/EUCAST [Tsuji 2019]).</p></div>
<div id=3D"F154535" class=3D"block pha drugH1Div"><span class=3D"drugH1">Me=
chanism of Action</span>
                  <p style=3D"text-indent:0em;display:inline">Colistimethat=
e (or the sodium salt [colistimethate sodium]) is the inactive prodrug that=
 is hydrolyzed to colistin, which acts as a cationic detergent and damages =
the bacterial cytoplasmic membrane causing leaking of intracellular substan=
ces and cell death.</p></div>
<div id=3D"F154548" class=3D"block phk drugH1Div"><span class=3D"drugH1">Ph=
armacokinetics (Adult Data Unless Noted)</span>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Absorption=
: Not absorbed from the GI tract, mucous membranes, or intact skin (<b>Note=
:</b> GI absorption has been observed in infants).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Distributi=
on:</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">CSF penetr=
ation:</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Infants, C=
hildren, and Adolescents =E2=89=A414 years: Colistin: 3% to 19%; may be inc=
reased in the presence of meningitis (Antachopoulos 2010).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Adults: Co=
listin: ~5% (Markantonis 2009).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">V<sub>d</s=
ub>:</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Neonates (=
GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: Colistin: 7.7 =C2=B1 9.3 L/kg (=
Nakwan 2016).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Children =
=E2=89=A52 years and Adolescents &lt;15 years: IV: Colistin: 0.6 =C2=B1 0.3=
 L/kg.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Adults:</p=
>
                  <p style=3D"text-indent:-2em;margin-left:8em;">
                     <i>Healthy volunteer:</i> IV: Colistimethate: 8.92 L; =
Colistin: 12.4 L (Couet 2012).</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">
                     <i>Critically ill:</i> IV: Colistimethate: 5.3 to 13.5=
 L; Colistin: 7.2 to 189 L (Couet 2012).</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">
                     <i>Cystic fibrosis:</i> IV: Colistimethate: 10.8 to 31=
.3 L (Li 2003).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Protein bi=
nding: 50%.</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Metabolism=
: Colistimethate sodium (inactive prodrug) is hydrolyzed to colistin (activ=
e form). <b>Note:</b> Only ~30% of colistimethate sodium is converted to co=
listin (Couet 2011).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Half-life =
elimination: IM, IV: All ages: Colistimethate: 2 to 3 hours.</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Neonates (=
GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: Colistin: 9 =C2=B1 6.5 hours (N=
akwan 2016).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Children =
=E2=89=A52 years and Adolescents &lt;15 years (critically ill): IV: Colisti=
n: 2.6 =C2=B1 0.4 hours (Wacharachaisurapol 2020).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Adults:</p=
>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>Critically ill:</i> IV: Colistimethate: 2.3 hours; =
Colistin: 14.4 hours (Plachouras 2009).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>Cystic fibrosis:</i> IV: Colistin: ~4 hours (Li 200=
3).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>End-stage renal disease patients receiving CAPD:</i=
> IV: Colistin: 13.2 hours (Koomanachai 2014).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Time to pe=
ak:</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Neonates (=
GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: Colistin: 1.3 =C2=B1 0.9 hours =
from end of 0.5-hour infusion (Nakwan 2016).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Children =
=E2=89=A52 years and Adolescents &lt;15 years: IV: Colistin: 1.1 =C2=B1 0.3=
 hours from end of 5-minute injection (Wacharachaisurapol 2020).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">Adults:</p=
>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>Healthy volunteers:</i> IV: Colistin: 2 hours (rang=
e: 1 to 4 hours) (Couet 2011).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>Critically ill:</i> IV: Colistin: ~7 hours (Plachou=
ras 2009).</p>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Excretion:=
 Primarily urine (as unchanged drug); most colistin recovered in the urine =
is from postexcretion hydrolysis of colistimethate sodium (Couet 2011).</p>=
</div>
<div id=3D"F58825283" class=3D"block phksp drugH1Div"><span class=3D"drugH1=
">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</sp=
an>
                  <p style=3D"text-indent:-2em;margin-left:2em;">Anti-infec=
tive considerations:</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <i>Parameters associated with efficacy:</i> Concentrat=
ion dependent; associated with area under the curve (AUC<sub>24</sub>)/mini=
mum inhibitory concentration (MIC), goal: AUC<sub>24</sub> at steady state =
~50 mg=E2=80=A2hour/L or an average plasma colistin concentration at steady=
 state (C<sub>ss,avg</sub>) of 2 mg/L (Abdul-Aziz 2020; ESCMID/EUCAST [Tsuj=
i 2019]).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">Organism s=
pecific:</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">
                     <i>P. aeruginosa</i>: Goal: <i>f</i>AUC<sub>0-24</sub>=
/MIC: 6.6 to 13.7 (Abdul-Aziz 2020; Cheah 2015).</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">
                     <i>A. baumannii</i>: Goal: <i>f</i>AUC<sub>0-24</sub>/=
MIC: 3.5 to 17.6 (Abdul-Aziz 2020; Cheah 2015).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <i>Expected drug concentrations in patients with norma=
l renal function:</i></p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <b>Note: </b>Reported concentrations are reflective of=
 active colistin component unless otherwise specified.</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <b>C<sub>max </sub>(peak):</b></p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">Neonates (=
GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: 5 mg colistin base activity (CB=
A)/kg, single dose: 3 =C2=B1 0.7 mg/L (Nakwan 2016).</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">Children =
=E2=89=A52 years of age and adolescents =E2=89=A415 years of age: IV:</p>
                  <p style=3D"text-indent:-2em;margin-left:10em;">1.7 to 2.=
5 mg CBA/kg, single dose: 4.1 =C2=B1 1.3 mg/L (Wacharachaisurapol 2020).</p=
>
                  <p style=3D"text-indent:-2em;margin-left:10em;">4 mg CBA/=
kg, single dose: 6.1 =C2=B1 2.4 mg/L (Wacharachaisurapol 2020).</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">Adults:</p=
>
                  <p style=3D"text-indent:-2em;margin-left:10em;">Healthy v=
olunteers: 2.5 mg/kg CBA IV every 12 hours, steady state: 1.79 =C2=B1 0.37 =
mg/L (Fan 2022).</p>
                  <p style=3D"text-indent:-2em;margin-left:10em;">Patients =
who are critically ill: 0.875 to 1.58 mg/kg CBA IV every 8 or 12 hours, ste=
ady state: 2.93 mg/L (Markou 2008).</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <b>AUC</b>
                     <b>
                        <sub></sub></b>
                     <b>(total):</b></p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">AUC<sub>0-=
24</sub>: Neonates (GA: 29 to 41 weeks; PNA: 5 to 15 days): IV: 5 mg CBA/kg=
, single dose: 21.1 =C2=B1 8.1 mg=E2=80=A2hour/L (Nakwan 2016).</p>
                  <p style=3D"text-indent:-2em;margin-left:8em;">Adults:</p=
>
                  <p style=3D"text-indent:-2em;margin-left:10em;">AUC<sub>0=
-12</sub>: Healthy volunteers: 2.5 mg/kg CBA IV every 12 hours, steady stat=
e: 15.28 =C2=B1 3.29 mg=E2=80=A2hour/L (Fan 2022).</p>
                  <p style=3D"text-indent:-2em;margin-left:10em;">AUC<sub>0=
-24</sub>: Patients who are critically ill: 0.875 to 1.58 mg/kg CBA IV ever=
y 8 or 12 hours, steady state: 12.8 mg=E2=80=A2hour/L (range: 6 to 20 mg=E2=
=80=A2hour/L) (Markou 2008).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <i>Postantibiotic effect: </i>Bacterial killing may co=
ntinue after colistin concentration falls below the MIC of targeted pathoge=
n and varies based on the organism, antimicrobial concentration, and durati=
on of antimicrobial exposure:</p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>A. baumannii: </i>0 to &gt;7 hours (Rasidin 2020).<=
/p>
                  <p style=3D"text-indent:-2em;margin-left:6em;">
                     <i>P. aeruginosa: </i>~1 to 1.5 hours (Bozkurt-G=C3=BC=
zel 2012).</p>
                  <p style=3D"text-indent:-2em;margin-left:4em;">
                     <i>Parameters associated with toxicity:</i> A C<sub>mi=
n </sub>&gt; ~2 to 2.4 mg/L has been associated with increased risk of neph=
rotoxicity (ESCMID/EUCAST [Tsuji 2019]; Forrest 2017; Horcajada 2016; Sorl=
=C3=AD 2013).</p></div>
<div id=3D"F6038587" class=3D"list fbnlist drugH1Div drugBrandNames"><span =
class=3D"drugH1">Brand Names: International</span><div class=3D"ibn-search =
drugBrandNames"></div>
<div class=3D"collapsible-indication brand-names-accordion drugBrandNames">=
<span class=3D"collapsible-indication-title">International Brand Names by C=
ountry</span><div class=3D"collapsible-indication-wrap-frame drugBrandNames=
"><div class=3D"collapsible-indication-wrap drugBrandNames">For country cod=
e abbreviations (<a class=3D"graphic graphic_table" rel=3D"external" href=
=3D"/d/html/116421">show table</a>)<br xmlns=3D"">=
<br><ul>
                     <li>
                        <span class=3D"countryCode">(AR)</span> <span class=
=3D"country">Argentina</span><span class=3D"countrySeparator">: </span><spa=
n class=3D"drugName">Alfacolin | Alficetin | Colistina richet | Colistina s=
urar pharma | Cotrelan | Espirotech | Klonistina | Nolisim | Toliscrin</spa=
n>;</li>
                     <li>
                        <span class=3D"countryCode">(AT)</span> <span class=
=3D"country">Austria</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colistin | Colistin astro | Tadim</span>;</li>
                     <li>
                        <span class=3D"countryCode">(BD)</span> <span class=
=3D"country">Bangladesh</span><span class=3D"countrySeparator">: </span><sp=
an class=3D"drugName">Gigabac | Megabac</span>;</li>
                     <li>
                        <span class=3D"countryCode">(BE)</span> <span class=
=3D"country">Belgium</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colistineb</span>;</li>
                     <li>
                        <span class=3D"countryCode">(BG)</span> <span class=
=3D"country">Bulgaria</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Colistin | Colistin tzf</span>;</li>
                     <li>
                        <span class=3D"countryCode">(BR)</span> <span class=
=3D"country">Brazil</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colis tek | Colistimetato de sodio | Promixin</span>;</li=
>
                     <li>
                        <span class=3D"countryCode">(CH)</span> <span class=
=3D"country">Switzerland</span><span class=3D"countrySeparator">: </span><s=
pan class=3D"drugName">Colistin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(CN)</span> <span class=
=3D"country">China</span><span class=3D"countrySeparator">: </span><span cl=
ass=3D"drugName">Colimycin | Ke li si an</span>;</li>
                     <li>
                        <span class=3D"countryCode">(CO)</span> <span class=
=3D"country">Colombia</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Coliject | Colintensin | Colis tek | Colistimetato de s=
odio | Colomycin | Nolisim | Olixato</span>;</li>
                     <li>
                        <span class=3D"countryCode">(CZ)</span> <span class=
=3D"country">Czech Republic</span><span class=3D"countrySeparator">: </span=
><span class=3D"drugName">Colistin | Colomycin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(DE)</span> <span class=
=3D"country">Germany</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colist | Colistiflex | Colistimethat natrium hikma | Col=
istin | Promixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(EC)</span> <span class=
=3D"country">Ecuador</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Alfacolin | Colistina</span>;</li>
                     <li>
                        <span class=3D"countryCode">(EE)</span> <span class=
=3D"country">Estonia</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colistin | Colixin | Colomycin | Elistin | Sodium colist=
imethate g.e.s</span>;</li>
                     <li>
                        <span class=3D"countryCode">(EG)</span> <span class=
=3D"country">Egypt</span><span class=3D"countrySeparator">: </span><span cl=
ass=3D"drugName">Colixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(ES)</span> <span class=
=3D"country">Spain</span><span class=3D"countrySeparator">: </span><span cl=
ass=3D"drugName">Colimicina | Colistimetato de sodio accord | Colistimetato=
 de Sodio Ges | Colistimetato de sodio xellia | Colixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(FI)</span> <span class=
=3D"country">Finland</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colimycin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(FR)</span> <span class=
=3D"country">France</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colimycine | Colistimethate sodique medac | Colistimethat=
e sodique panpharma</span>;</li>
                     <li>
                        <span class=3D"countryCode">(GB)</span> <span class=
=3D"country">United Kingdom</span><span class=3D"countrySeparator">: </span=
><span class=3D"drugName">Colomycin | Promixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(GR)</span> <span class=
=3D"country">Greece</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colistin | Colistin/norma</span>;</li>
                     <li>
                        <span class=3D"countryCode">(HK)</span> <span class=
=3D"country">Hong Kong</span><span class=3D"countrySeparator">: </span><spa=
n class=3D"drugName">Colomycin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(HR)</span> <span class=
=3D"country">Croatia</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Kolistin Alvogen</span>;</li>
                     <li>
                        <span class=3D"countryCode">(HU)</span> <span class=
=3D"country">Hungary</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colistimethat natrium hikma | Colistin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(IE)</span> <span class=
=3D"country">Ireland</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colomycin | Promixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(IL)</span> <span class=
=3D"country">Israel</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Coliracin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(IN)</span> <span class=
=3D"country">India</span><span class=3D"countrySeparator">: </span><span cl=
ass=3D"drugName">Colibug | Colicraft | Colifect | Coligetz | Colimista | Co=
lina | Colinem | Colirem | Colist | Colisvio | Coly monas | Critimycin | El=
istin | Ibicolist | Kabimethate | Kallistro | Kolax | Koolmete | Kuzet | My=
xitin | Neolistim | Promistin | Remergin | Resilistin | Sava cms | Tough | =
Wockstin | Xylistin | Xylistin n | Zizant | Zolineg | Zycolis</span>;</li>
                     <li>
                        <span class=3D"countryCode">(IT)</span> <span class=
=3D"country">Italy</span><span class=3D"countrySeparator">: </span><span cl=
ass=3D"drugName">Colimicina | Colistimetato accord | Colistimetato Hikma | =
Colistimetato xellia | Pseudoneb</span>;</li>
                     <li>
                        <span class=3D"countryCode">(JO)</span> <span class=
=3D"country">Jordan</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colistin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(JP)</span> <span class=
=3D"country">Japan</span><span class=3D"countrySeparator">: </span><span cl=
ass=3D"drugName">Aldreb | Colimycin kaken | Colimycin kayaku</span>;</li>
                     <li>
                        <span class=3D"countryCode">(KR)</span> <span class=
=3D"country">Korea, Republic of</span><span class=3D"countrySeparator">: </=
span><span class=3D"drugName">Colimycin | Colis | Fucolistimetate | X colis=
tin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(KW)</span> <span class=
=3D"country">Kuwait</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colistin JPI</span>;</li>
                     <li>
                        <span class=3D"countryCode">(LB)</span> <span class=
=3D"country">Lebanon</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colomycin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(LT)</span> <span class=
=3D"country">Lithuania</span><span class=3D"countrySeparator">: </span><spa=
n class=3D"drugName">Colimycine | Colistin tzf</span>;</li>
                     <li>
                        <span class=3D"countryCode">(LV)</span> <span class=
=3D"country">Latvia</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colimycine | Colistin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(MA)</span> <span class=
=3D"country">Morocco</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colimycine</span>;</li>
                     <li>
                        <span class=3D"countryCode">(MX)</span> <span class=
=3D"country">Mexico</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colmesdant | Darogen</span>;</li>
                     <li>
                        <span class=3D"countryCode">(MY)</span> <span class=
=3D"country">Malaysia</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Colistimethate | Colomycin | Xelcol</span>;</li>
                     <li>
                        <span class=3D"countryCode">(NL)</span> <span class=
=3D"country">Netherlands</span><span class=3D"countrySeparator">: </span><s=
pan class=3D"drugName">Colistimethaatnatrium eureco-pharma | Kolneb | Tadim=
</span>;</li>
                     <li>
                        <span class=3D"countryCode">(NO)</span> <span class=
=3D"country">Norway</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colimycin | Colomycin | Promixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PE)</span> <span class=
=3D"country">Peru</span><span class=3D"countrySeparator">: </span><span cla=
ss=3D"drugName">Colismet | Colistina | Colistipharm | Coltirox</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PH)</span> <span class=
=3D"country">Philippines</span><span class=3D"countrySeparator">: </span><s=
pan class=3D"drugName">Colisan 2</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PK)</span> <span class=
=3D"country">Pakistan</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Coliate | Colicraft | Colimate | Colistat | Colistim | =
Nogotex</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PL)</span> <span class=
=3D"country">Poland</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colimycine | Colistin | Colomycin | Promixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PR)</span> <span class=
=3D"country">Puerto Rico</span><span class=3D"countrySeparator">: </span><s=
pan class=3D"drugName">Colistimethate | Coly-mycin m</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PT)</span> <span class=
=3D"country">Portugal</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Colimicina | Colistimetato accord | Colistimetato Hikma=
 | Colistin Generis | Colixin | Colomycin ip</span>;</li>
                     <li>
                        <span class=3D"countryCode">(PY)</span> <span class=
=3D"country">Paraguay</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Colistina bioethic | Colistina catedral | Colistina das=
anti | Colistina dima | Colistina dutriec | Colistina gautier | Colistina r=
ichet | Etibac | Nolisim</span>;</li>
                     <li>
                        <span class=3D"countryCode">(RO)</span> <span class=
=3D"country">Romania</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colistina</span>;</li>
                     <li>
                        <span class=3D"countryCode">(RU)</span> <span class=
=3D"country">Russian Federation</span><span class=3D"countrySeparator">: </=
span><span class=3D"drugName">Colistimetat</span>;</li>
                     <li>
                        <span class=3D"countryCode">(SA)</span> <span class=
=3D"country">Saudi Arabia</span><span class=3D"countrySeparator">: </span><=
span class=3D"drugName">Colistin JPI</span>;</li>
                     <li>
                        <span class=3D"countryCode">(SE)</span> <span class=
=3D"country">Sweden</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Tadim</span>;</li>
                     <li>
                        <span class=3D"countryCode">(SI)</span> <span class=
=3D"country">Slovenia</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Colistin | Colistina generis | Colomycin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(TH)</span> <span class=
=3D"country">Thailand</span><span class=3D"countrySeparator">: </span><span=
 class=3D"drugName">Colistate | Colistin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(TN)</span> <span class=
=3D"country">Tunisia</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colimycine | Colixin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(TR)</span> <span class=
=3D"country">Turkey</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colimycin | Colitim | Kolisod | Kolistate | Kolistipol | =
Lixicol</span>;</li>
                     <li>
                        <span class=3D"countryCode">(TW)</span> <span class=
=3D"country">Taiwan</span><span class=3D"countrySeparator">: </span><span c=
lass=3D"drugName">Colimycin | Colistin | Costim | Locolin | Metacoli</span>=
;</li>
                     <li>
                        <span class=3D"countryCode">(UA)</span> <span class=
=3D"country">Ukraine</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Colistin alvogen</span>;</li>
                     <li>
                        <span class=3D"countryCode">(UY)</span> <span class=
=3D"country">Uruguay</span><span class=3D"countrySeparator">: </span><span =
class=3D"drugName">Alfacolin | Avagal | Colistina Permatec | Colistina rich=
et | Toliscrin</span>;</li>
                     <li>
                        <span class=3D"countryCode">(ZA)</span> <span class=
=3D"country">South Africa</span><span class=3D"countrySeparator">: </span><=
span class=3D"drugName">Colimycin</span></li></ul></div>
</div>
</div>
</div>
</div><div id=3D"references" class=3D"headingAnchor"><ol id=3D"reference">
<li>
<div class=3D"reference" id=3D"lexi-content-ref-31487382">
                 =20
                     <a name=3D"31487382"></a>Abbott L, Plummer A, Hoo ZH, =
Wildman M. Duration of intravenous antibiotic therapy in people with cystic=
 fibrosis. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD006682. doi:10.10=
02/14651858.CD006682.pub6<span class=3D"pubmed-id"> [PubMed <a id=3D"314873=
82" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-co=
listimethate-drug-information/abstract-text/31487382/pubmed">31487382</a>]<=
/span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-32383061">
                 =20
                     <a name=3D"32383061"></a>Abdul-Aziz MH, Alffenaar JC, =
Bassetti M, et al; Infection Section of European Society of Intensive Care =
Medicine (ESICM); Pharmacokinetic/Pharmacodynamic and Critically Ill Patien=
t Study Groups of European Society of Clinical Microbiology and Infectious =
Diseases (ESCMID); Infectious Diseases Group of International Association o=
f Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections=
 in the ICU and Sepsis Working Group of International Society of Antimicrob=
ial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in criti=
cally ill adult patients: a position paper. <i>Intensive Care Med.</i> 2020=
;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class=3D"pubmed-id"> =
[PubMed <a id=3D"32383061" target=3D"_blank" href=3D"https://www.uptodate.c=
om/contents/colistin-colistimethate-drug-information/abstract-text/32383061=
/pubmed">32383061</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-31844014">
                 =20
                     <a name=3D"31844014"></a>Aguilera-Alonso D, Escosa-Gar=
c=C3=ADa L, Saavedra-Lozano J, Cercenado E, Baquero-Artigao F. Carbapenem-r=
esistant gram-negative bacterial infections in children. <i>Antimicrob Agen=
ts Chemother</i>. 2020;64(3):e02183-19. doi:10.1128/AAC.02183-19<span class=
=3D"pubmed-id"> [PubMed <a id=3D"31844014" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/31844014/pubmed">31844014</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-30709064">
                 =20
                     <a name=3D"30709064"></a>Aitullina A, Kr=C5=ABmi=C5=86=
a A, Svirskis =C5=A0, Purvi=C5=86a S. Colistin use in patients with extreme=
 renal function: from dialysis to augmented clearance. <i>Medicina (Kaunas)=
</i>. 2019;55(2):33. doi:10.3390/medicina55020033<span class=3D"pubmed-id">=
 [PubMed <a id=3D"30709064" target=3D"_blank" href=3D"https://www.uptodate.=
com/contents/colistin-colistimethate-drug-information/abstract-text/3070906=
4/pubmed">30709064</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23840000">
                 =20
                     <a name=3D"23840000"></a>Akajagbor DS, Wilson SL, Sher=
e-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. Higher incidence of acute kid=
ney injury with intravenous colistimethate sodium compared with polymyxin B=
 in critically ill patients at a tertiary care medical center. <i>Clin Infe=
ct Dis</i>. 2013;57(9):1300-1303.<span class=3D"pubmed-id"> [PubMed <a id=
=3D"23840000" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/23840000/pubmed">2384=
0000</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33108082">
                 =20
                     <a name=3D"33108082"></a>Aksoy GK, =C3=96zyaz=C4=B1c=
=C4=B1-=C3=96zkan SE, Tezel G, Dayar GT, K=C3=B6=C5=9Fker M, Do=C4=9Fan =C3=
=87S. Assessment of colistin related side effects in premature neonates. <i=
>Turk J Pediatr</i>. 2020;62(5):795-801. doi:10.24953/turkjped.2020.05.011<=
span class=3D"pubmed-id"> [PubMed <a id=3D"33108082" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/33108082/pubmed">33108082</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24584997">
                 =20
                     <a name=3D"24584997"></a>Alan S, Yildiz D, Erdeve O, e=
t al. Efficacy and safety of intravenous colistin in preterm infants with n=
osocomial sepsis caused by <i>Acinetobacter baumannii</i>. <i>Am J Perinato=
l</i>. 2014;31(12):1079-1086. doi:10.1055/s-0034-1371361<span class=3D"pubm=
ed-id"> [PubMed <a id=3D"24584997" target=3D"_blank" href=3D"https://www.up=
todate.com/contents/colistin-colistimethate-drug-information/abstract-text/=
24584997/pubmed">24584997</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34955517">
                 =20
                     <a name=3D"34955517"></a>Almangour TA, Alsubaie S, Gho=
nem L, Almohaini HA, Mohammed Bakheet H, Ikhlass A. Ceftazidime-avibactam f=
or the treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> centr=
al nervous system infection in pediatric patient: a case report. <i>Pediatr=
 Infect Dis J</i>. 2022;41(5):436-438. doi:10.1097/INF.0000000000003439<spa=
n class=3D"pubmed-id"> [PubMed <a id=3D"34955517" target=3D"_blank" href=3D=
"https://www.uptodate.com/contents/colistin-colistimethate-drug-information=
/abstract-text/34955517/pubmed">34955517</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-15705991">
                 =20
                     <a name=3D"15705991"></a>Alothman GA, Ho B, Alsaadi MM=
, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. <i=
>Chest</i>. 2005;127(2):522-529.<span class=3D"pubmed-id"> [PubMed <a id=3D=
"15705991" target=3D"_blank" href=3D"https://www.uptodate.com/contents/coli=
stin-colistimethate-drug-information/abstract-text/15705991/pubmed">1570599=
1</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28841583">
                 =20
                     <a name=3D"28841583"></a>Al Yazidi LS, McMullan B, Koh=
an S, Palasanthiran P. Persistent gram-negative neurosurgical meningitis in=
 a neonate, successfully treated with intraventricular colistin: case repor=
t and review of the literature. <i>Pediatr Infect Dis J</i>. 2018;37(3):e79=
-e81. doi:10.1097/INF.0000000000001743<span class=3D"pubmed-id"> [PubMed <a=
 id=3D"28841583" target=3D"_blank" href=3D"https://www.uptodate.com/content=
s/colistin-colistimethate-drug-information/abstract-text/28841583/pubmed">2=
8841583</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-32198160">
                 =20
                     <a name=3D"32198160"></a>Ambreen G, Salat MS, Hussain =
K, et al. Efficacy of colistin in multidrug-resistant neonatal sepsis: expe=
rience from a tertiary care center in Karachi, Pakistan. <i>Arch Dis Child<=
/i>. 2020;105(9):830-836. doi:10.1136/archdischild-2019-318067<span class=
=3D"pubmed-id"> [PubMed <a id=3D"32198160" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/32198160/pubmed">32198160</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-AAP.1">
                 =20
                     <a name=3D"AAP.1"></a>American Academy of Pediatrics. =
Dicloxacillin. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i=
>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32=
nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33782000">
                 =20
                     <a name=3D"33782000"></a>Antachopoulos C, Geladari A, =
Landersdorfer CB, et al. Population pharmacokinetics and outcomes of critic=
ally ill pediatric patients treated with intravenous colistin at higher tha=
n recommended doses. <i>Antimicrob Agents Chemother</i>. 2021;65(6):e00002-=
21. doi:10.1128/AAC.00002-21<span class=3D"pubmed-id"> [PubMed <a id=3D"337=
82000" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin=
-colistimethate-drug-information/abstract-text/33782000/pubmed">33782000</a=
>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28650936">
                 =20
                     <a name=3D"28650936"></a>Antachopoulos C, Iosifidis E.=
 Colistin use in neonates and children with infections due to carbapenem-re=
sistant bacteria. <i>Pediatr Infect Dis J</i>. 2017;36(9):905-907. doi:10.1=
097/INF.0000000000001655<span class=3D"pubmed-id"> [PubMed <a id=3D"2865093=
6" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-col=
istimethate-drug-information/abstract-text/28650936/pubmed">28650936</a>]</=
span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20585114">
                 =20
                     <a name=3D"20585114"></a>Antachopoulos C, Karvanen M, =
Iosifidis E, et al. Serum and cerebrospinal fluid levels of colistin in ped=
iatric patients. <i>Antimicrob Agents Chemother</i>. 2010;54(9):3985-3987. =
doi:10.1128/AAC.01799-09<span class=3D"pubmed-id"> [PubMed <a id=3D"2058511=
4" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-col=
istimethate-drug-information/abstract-text/20585114/pubmed">20585114</a>]</=
span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33713930">
                 =20
                     <a name=3D"33713930"></a>Atag E, Unal F, Arslan H, et =
al. The effect of nebulized antibiotics in children with tracheostomy. <i>I=
nt J Pediatr Otorhinolaryngol</i>. 2021;143:110665. doi:10.1016/j.ijporl.20=
21.110665<span class=3D"pubmed-id"> [PubMed <a id=3D"33713930" target=3D"_b=
lank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dru=
g-information/abstract-text/33713930/pubmed">33713930</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33575996">
                 =20
                     <a name=3D"33575996"></a>Ayhan M, Kalem AK, Hasanoglu =
I, et al. Intrathecal and intraventricular administration of antibiotics in=
 gram-negative nosocomial meningitis in a research hospital in Turkey. <i>T=
urk Neurosurg</i>. 2021;31(3):348-354. doi:10.5137/1019-5149.JTN.29844-20.2=
<span class=3D"pubmed-id"> [PubMed <a id=3D"33575996" target=3D"_blank" hre=
f=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informa=
tion/abstract-text/33575996/pubmed">33575996</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Baddour.1">
                 =20
                     <a name=3D"Baddour.1"></a>Baddour L, Flynn PM, Fekete =
T. Infections of cerebrospinal fluid shunts and other devices. Post TW, ed.=
 UpToDate. Waltham, MA: UpToDate Inc. <a target=3D"_blank" href=3D"http://w=
ww.uptodate.com/">http://www.uptodate.com</a>. Accessed June 27, 2023.</div=
>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24728736">
                 =20
                     <a name=3D"24728736"></a>Bargiacchi O, Rossati A, Car =
P, et al. Intrathecal/intraventricular colistin in external ventricular dev=
ice-related infections by multi-drug resistant Gram negative bacteria: case=
 reports and review. <i>Infection</i>. 2014;42(5):801-809. doi:10.1007/s150=
10-014-0618-0<span class=3D"pubmed-id"> [PubMed <a id=3D"24728736" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/24728736/pubmed">24728736</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Barker.1">
                 =20
                     <a name=3D"Barker.1"></a>Barker AF. Bronchiectasis in =
adults: maintaining lung health. Post TW, ed. UpToDate. Waltham, MA: UpToDa=
te Inc. <a target=3D"_blank" href=3D"http://www.uptodate.com/">http://www.u=
ptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-9311714">
                 =20
                     <a name=3D"9311714"></a>Bauldoff GS, Nunley DR, Manzet=
ti JD, et al. Use of Aerosolized Colistin in Cystic Fibrosis Patients Await=
ing Lung Transplantation. <i>Transplantation</i>. 1997;64(5):748-752.<span =
class=3D"pubmed-id"> [PubMed <a id=3D"9311714" target=3D"_blank" href=3D"ht=
tps://www.uptodate.com/contents/colistin-colistimethate-drug-information/ab=
stract-text/9311714/pubmed">9311714</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-15190037">
                 =20
                     <a name=3D"15190037"></a>Benifla M, Zucker G, Cohen A,=
 Alkan M. Successful treatment of Acinetobacter meningitis with intrathecal=
 polymyxin E. <i>J Antimicrob Chemother</i>. 2004;54(1):290-292. doi:10.109=
3/jac/dkh289<span class=3D"pubmed-id"> [PubMed <a id=3D"15190037" target=3D=
"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-=
drug-information/abstract-text/15190037/pubmed">15190037</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25630411">
                 =20
                     <a name=3D"25630411"></a>Bergen PJ, Bulman ZP, Saju S,=
 et al. Polymyxin combinations: pharmacokinetics and pharmacodynamics for r=
ationale use. <i>Pharmacotherapy</i>. 2015;35(1):34-42. doi:10.1002/phar.15=
37<span class=3D"pubmed-id"> [PubMed <a id=3D"25630411" target=3D"_blank" h=
ref=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-infor=
mation/abstract-text/25630411/pubmed">25630411</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-11706322">
                 =20
                     <a name=3D"11706322"></a>Beringer P. The Clinical Use =
of Colistin in Patients With Cystic Fibrosis. <i>Curr Opin Pulm Med</i>. 20=
01;7(6):434-440.<span class=3D"pubmed-id"> [PubMed <a id=3D"11706322" targe=
t=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimeth=
ate-drug-information/abstract-text/11706322/pubmed">11706322</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-15658071">
                 =20
                     <a name=3D"15658071"></a>Berlana D, Llop JW, Fort E. B=
adia MB, J=C3=B3dar R. Use of colistin in the treatment of multiple-drug-re=
sistant gram-negative infections. <i>Am J Health-Syst Pharm</i>. 2005;62(1)=
:39-47.<span class=3D"pubmed-id"> [PubMed <a id=3D"15658071" target=3D"_bla=
nk" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-=
information/abstract-text/15658071/pubmed">15658071</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-29441476">
                 =20
                     <a name=3D"29441476"></a>Bilbao-Meseguer I, Rodr=C3=AD=
guez-Gasc=C3=B3n A, Barrasa H, Isla A, Solin=C3=ADs M=C3=81. Augmented rena=
l clearance in critically ill patients: a systematic review. <i>Clin Pharma=
cokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class=
=3D"pubmed-id"> [PubMed <a id=3D"29441476" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/29441476/pubmed">29441476</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-1763528">
                 =20
                     <a name=3D"1763528"></a>Bosso JA, Liptak CA, Seilheime=
r DK, et al. Toxicity of Colistin in Cystic Fibrosis Patients. <i>DICP</i>.=
 1991;25(11):1168-1170.<span class=3D"pubmed-id"> [PubMed <a id=3D"1763528"=
 target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colis=
timethate-drug-information/abstract-text/1763528/pubmed">1763528</a>]</span=
>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22126897">
                 =20
                     <a name=3D"22126897"></a>Bozkurt-G=C3=BCzel C, Ger=C3=
=A7eker AA. Post-antibiotic effect of colistin, alone and in combination wi=
th amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosi=
s patients. <i>J Antibiot (Tokyo).</i> 2012;65(2):83-86. doi:10.1038/ja.201=
1.101<span class=3D"pubmed-id"> [PubMed <a id=3D"22126897" target=3D"_blank=
" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-in=
formation/abstract-text/22126897/pubmed">22126897</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28135233">
                 =20
                     <a name=3D"28135233"></a>=C3=87a=C4=9Fan E, K=C4=B1ray=
 Ba=C5=9F E, Asker HS. Use of colistin in a neonatal intensive care unit: A=
 cohort study of 65 patients. <i>Med Sci Monit</i>. 2017;23:548-554. doi:10=
.12659/msm.898213<span class=3D"pubmed-id"> [PubMed <a id=3D"28135233" targ=
et=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimet=
hate-drug-information/abstract-text/28135233/pubmed">28135233</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19892577">
                 =20
                     <a name=3D"19892577"></a>Cascio A, Conti A, Sinardi L,=
 et al. Post-neurosurgical multidrug-resistant <i>Acinetobacter baumannii</=
i> meningitis successfully treated with intrathecal colistin. A new case an=
d a systematic review of the literature. <i>Int J Infect Dis</i>. 2010;14(7=
):e572-e579. doi:10.1016/j.ijid.2009.06.032<span class=3D"pubmed-id"> [PubM=
ed <a id=3D"19892577" target=3D"_blank" href=3D"https://www.uptodate.com/co=
ntents/colistin-colistimethate-drug-information/abstract-text/19892577/pubm=
ed">19892577</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-35349496">
                 =20
                     <a name=3D"35349496"></a>Castagnola E, Ricci E, Marian=
i M. Infections due to antibiotic-resistant gram-negative bacteria in pedia=
trics: possible management strategies. <i>Pediatr Infect Dis J</i>. 2022;41=
(7):e283-e285. doi:10.1097/INF.0000000000003528<span class=3D"pubmed-id"> [=
PubMed <a id=3D"35349496" target=3D"_blank" href=3D"https://www.uptodate.co=
m/contents/colistin-colistimethate-drug-information/abstract-text/35349496/=
pubmed">35349496</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26318190">
                 =20
                     <a name=3D"26318190"></a>Cheah SE, Wang J, Nguyen VT, =
Turnidge JD, Li J, Nation RL. New pharmacokinetic/pharmacodynamic studies o=
f systemically administered colistin against Pseudomonas aeruginosa and Aci=
netobacter baumannii in mouse thigh and lung infection models: smaller resp=
onse in lung infection. <i>J Antimicrob Chemother.</i> 2015;70(12):3291-329=
7. doi:10.1093/jac/dkv267<span class=3D"pubmed-id"> [PubMed <a id=3D"263181=
90" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-co=
listimethate-drug-information/abstract-text/26318190/pubmed">26318190</a>]<=
/span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-32773667">
                 =20
                     <a name=3D"32773667"></a>Chin MKY, Hsia Y, Goossens H,=
 et al. Evidence of dose variability and dosing below the FDA and EMA recom=
mendations for intravenous colistin (polymyxin E) use in children and neona=
tes. <i>Pediatr Infect Dis J</i>. 2020;39(11):1032-1034. doi:10.1097/INF.00=
00000000002847<span class=3D"pubmed-id"> [PubMed <a id=3D"32773667" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/32773667/pubmed">32773667</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-31872226">
                 =20
                     <a name=3D"31872226"></a>Chiotos K, Hayes M, Gerber JS=
, Tamma PD. Treatment of carbapenem-resistant Enterobacteriaceae infections=
 in children. <i>J Pediatric Infect Dis Soc</i>. 2020;9(1):56-66. doi:10.10=
93/jpids/piz085<span class=3D"pubmed-id"> [PubMed <a id=3D"31872226" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/31872226/pubmed">31872226</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference">
                  Coly-Mycin M (colistimethate sodium) [prescribing informa=
tion]. Chestnut Ridge, NY: Par Pharmaceutical; February 2018.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-11098334">
                 =20
                     <a name=3D"11098334"></a>Conway SP, Etherington C, Mun=
day J, Goldman MH, Strong JJ, Wootton M. Safety and tolerability of bolus i=
ntravenous colistin in acute respiratory exacerbations in adults with cysti=
c fibrosis. <i>Ann Pharmacother</i>. 2000;34(11):1238-1242.<span class=3D"p=
ubmed-id"> [PubMed <a id=3D"11098334" target=3D"_blank" href=3D"https://www=
.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-te=
xt/11098334/pubmed">11098334</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-9487348">
                 =20
                     <a name=3D"9487348"></a>Conway SP, Pond MN, Watson A, =
et al. Intravenous Colistin Sulphomethate in Acute Respiratory Exacerbation=
s in Adult Patients With Cystic Fibrosis. <i>Thorax</i>. 1997;52(11):987-99=
3.<span class=3D"pubmed-id"> [PubMed <a id=3D"9487348" target=3D"_blank" hr=
ef=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inform=
ation/abstract-text/9487348/pubmed">9487348</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-21988234">
                 =20
                     <a name=3D"21988234"></a>Couet W, Gr=C3=A9goire N, Mar=
chand S, Mimoz O. Colistin pharmacokinetics: the fog is lifting. <i>Clin Mi=
crobiol Infect</i>. 2012;18(1):30-39.<span class=3D"pubmed-id"> [PubMed <a =
id=3D"21988234" target=3D"_blank" href=3D"https://www.uptodate.com/contents=
/colistin-colistimethate-drug-information/abstract-text/21988234/pubmed">21=
988234</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-21544080">
                 =20
                     <a name=3D"21544080"></a>Couet W, Gr=C3=A9goire N, Gob=
in P, et al. Pharmacokinetics of colistin and colistimethate sodium after a=
 single 80-mg intravenous dose of CMS in young healthy volunteers. <i>Clin =
Pharmacol Ther</i>. 2011;89(6):875-879.<span class=3D"pubmed-id"> [PubMed <=
a id=3D"21544080" target=3D"_blank" href=3D"https://www.uptodate.com/conten=
ts/colistin-colistimethate-drug-information/abstract-text/21544080/pubmed">=
21544080</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22423120">
                 =20
                     <a name=3D"22423120"></a>Dalfino L, Puntillo F, Mosca =
A, et al. High-dose, extended-interval colistin administration in criticall=
y ill patients: is this the right dosing strategy? A preliminary study. <i>=
Clin Infect Dis</i>. 2012;54(12):1720-1726.<span class=3D"pubmed-id"> [PubM=
ed <a id=3D"22423120" target=3D"_blank" href=3D"https://www.uptodate.com/co=
ntents/colistin-colistimethate-drug-information/abstract-text/22423120/pubm=
ed">22423120</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19460268">
                 =20
                     <a name=3D"19460268"></a>Dalgic N, Ceylan Y, Sancar M,=
 et al. Successful treatment of multidrug-resistant Acinetobacter baumannii=
 ventriculitis with intravenous and intraventricular colistin. <i>Ann Trop =
Paediatr</i>. 2009;29(2):141-147.<span class=3D"pubmed-id"> [PubMed <a id=
=3D"19460268" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/19460268/pubmed">1946=
0268</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26228051">
                 =20
                     <a name=3D"26228051"></a>De Bonis P, Lofrese G, Scoppe=
ttuolo G, et al. Intraventricular versus intravenous colistin for the treat=
ment of extensively drug resistant <i>Acinetobacter baumannii</i> meningiti=
s.<i> Eur J Neurol</i>. 2016;23(1):68-75. doi:10.1111/ene.12789<span class=
=3D"pubmed-id"> [PubMed <a id=3D"26228051" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/26228051/pubmed">26228051</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34013828">
                 =20
                     <a name=3D"34013828"></a>Deniz M, Tap=C4=B1s=C4=B1z A,=
 B=C3=B6rcek A=C3=96, Tezer H. Intraventricular treatment of paediatric men=
ingitis due to extensively drug-resistant Gram-negative bacteria: two case =
reports and review of the literature. <i>J Chemother</i>. 2021;33(7):509-51=
6. doi:10.1080/1120009X.2021.1920249<span class=3D"pubmed-id"> [PubMed <a i=
d=3D"34013828" target=3D"_blank" href=3D"https://www.uptodate.com/contents/=
colistin-colistimethate-drug-information/abstract-text/34013828/pubmed">340=
13828</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20660694">
                 =20
                     <a name=3D"20660694"></a>Deryke CA, Crawford AJ, Uddin=
 N, Wallace MR. Colistin dosing and nephrotoxicity in a large community tea=
ching hospital. <i>Antimicrob Agents Chemother</i>. 2010;54(10):4503-4505.<=
span class=3D"pubmed-id"> [PubMed <a id=3D"20660694" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/20660694/pubmed">20660694</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-11106223">
                 =20
                     <a name=3D"11106223"></a>D=C3=B6ring G, Conway SP, Hei=
jerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cyst=
ic fibrosis: a European consensus. <i>Eur Respir J</i>. 2000;16(4):749-767.=
 doi:10.1034/j.1399-3003.2000.16d30.x<span class=3D"pubmed-id"> [PubMed <a =
id=3D"11106223" target=3D"_blank" href=3D"https://www.uptodate.com/contents=
/colistin-colistimethate-drug-information/abstract-text/11106223/pubmed">11=
106223</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24274315">
                 =20
                     <a name=3D"24274315"></a>Doshi NM, Cook CH, Mount KL, =
et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negati=
ve pneumonia in the critically ill: a retrospective study. <i>BMC Anesthesi=
ology</i>. 2013;13(1):45.<span class=3D"pubmed-id"> [PubMed <a id=3D"242743=
15" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-co=
listimethate-drug-information/abstract-text/24274315/pubmed">24274315</a>]<=
/span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33539569">
                 =20
                     <a name=3D"33539569"></a>Downes KJ, Goldman JL. Too mu=
ch of a good thing: defining antimicrobial therapeutic targets to minimize =
toxicity. <i>Clin Pharmacol Ther</i>. 2021;109(4):905-917. doi:10.1002/cpt.=
2190<span class=3D"pubmed-id"> [PubMed <a id=3D"33539569" target=3D"_blank"=
 href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inf=
ormation/abstract-text/33539569/pubmed">33539569</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-EMA.1">
                 =20
                     <a name=3D"EMA.1"></a>European Medicine Agency (EMA). =
European Medicines Agency completes review of polymyxin-based medicine. Pub=
lished October 24, 2014.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-EMC.1">
                 =20
                     <a name=3D"EMC.1"></a>EMC Web site. Colomycin Injectio=
n. https://www.medicines.org.uk/emc/medicine/1590. Accessed December 19, 20=
17.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34599691">
                 =20
                     <a name=3D"34599691"></a>Evans L, Rhodes A, Alhazzani =
W, et al. Surviving sepsis campaign: international guidelines for managemen=
t of sepsis and septic shock 2021. <i>Intensive Care Med</i>. 2021;47(11):1=
181-1247. doi:10.1007/s00134-021-06506-y<span class=3D"pubmed-id"> [PubMed =
<a id=3D"34599691" target=3D"_blank" href=3D"https://www.uptodate.com/conte=
nts/colistin-colistimethate-drug-information/abstract-text/34599691/pubmed"=
>34599691</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Expert.DOR">
                 =20
                     <a name=3D"Expert.DOR"></a>Expert opinion. Senior Rena=
l Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts=
, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-17126534">
                 =20
                     <a name=3D"17126534"></a>Falagas ME, Bliziotis IA, Tam=
 VH. Intraventricular or intrathecal use of polymyxins in patients with Gra=
m-negative meningitis: a systematic review of the available evidence. <i>In=
t J Antimicrob Agents</i>. 2007;29(1):9-25. doi: 10.1016/j.ijantimicag.2006=
.08.024.<span class=3D"pubmed-id"> [PubMed <a id=3D"17126534" target=3D"_bl=
ank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug=
-information/abstract-text/17126534/pubmed">17126534</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-16723606">
                 =20
                     <a name=3D"16723606"></a>Falagas ME, Kasiakou SK. Use =
of international units when dosing colistin will help decrease confusion re=
lated to various formulations of the drug around the world. <i>Antimicrob A=
gents Chemother</i>. 2006;50(6):2274-2275.<span class=3D"pubmed-id"> [PubMe=
d <a id=3D"16723606" target=3D"_blank" href=3D"https://www.uptodate.com/con=
tents/colistin-colistimethate-drug-information/abstract-text/16723606/pubme=
d">16723606</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20658485">
                 =20
                     <a name=3D"20658485"></a>Falagas ME, Sideri G, Korbila=
 IP, Vouloumanou EK, Papadatos JH, Kafetzis DA. Inhaled colistin for the tr=
eatment of tracheobronchitis and pneumonia in critically ill children witho=
ut cystic fibrosis. <i>Pediatr Pulmonol.</i> 2010;45(11):1135-1140<span cla=
ss=3D"pubmed-id"> [PubMed <a id=3D"20658485" target=3D"_blank" href=3D"http=
s://www.uptodate.com/contents/colistin-colistimethate-drug-information/abst=
ract-text/20658485/pubmed">20658485</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-35740204">
                 =20
                     <a name=3D"35740204"></a>Fan Y, Li Y, Chen Y, et al. P=
harmacokinetics and pharmacodynamics of colistin methanesulfonate in health=
y Chinese subjects after multi-dose regimen. <i>Antibiotics (Basel).</i> 20=
22;11(6):798. doi:10.3390/antibiotics11060798<span class=3D"pubmed-id"> [Pu=
bMed <a id=3D"35740204" target=3D"_blank" href=3D"https://www.uptodate.com/=
contents/colistin-colistimethate-drug-information/abstract-text/35740204/pu=
bmed">35740204</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-10825065">
                 =20
                     <a name=3D"10825065"></a>Fernandez-Viladrich P, Corbel=
la X, Corral L, Tubau F, Mateu A. Successful treatment of ventriculitis due=
 to carbapenem-resistant <i>Acinetobacter baumannii</i> with intraventricul=
ar colistin sulfomethate sodium. <i>Clin Infect Dis</i>. 1999;28(4):916-917=
. doi:10.1086/517243<span class=3D"pubmed-id"> [PubMed <a id=3D"10825065" t=
arget=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colisti=
methate-drug-information/abstract-text/10825065/pubmed">10825065</a>]</span=
>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28893780">
                 =20
                     <a name=3D"28893780"></a>Forrest A, Garonzik SM, Thaml=
ikitkul V, et al. Pharmacokinetic/Toxicodynamic analysis of colistin-associ=
ated acute kidney injury in critically ill patients. <i>Antimicrob Agents C=
hemother.</i> 2017;61(11):e01367-17. doi:10.1128/AAC.01367-17<span class=3D=
"pubmed-id"> [PubMed <a id=3D"28893780" target=3D"_blank" href=3D"https://w=
ww.uptodate.com/contents/colistin-colistimethate-drug-information/abstract-=
text/28893780/pubmed">28893780</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26801512">
                 =20
                     <a name=3D"26801512"></a>Fotakopoulos G, Makris D, Cha=
tzi M, et al. Outcomes in meningitis/ventriculitis treated with intravenous=
 or intraventricular plus intravenous colistin. <i>Acta Neurochir (Wien)</i=
>. 2016;158(3):603-610; discussion 610. doi:10.1007/s00701-016-2702-y<span =
class=3D"pubmed-id"> [PubMed <a id=3D"26801512" target=3D"_blank" href=3D"h=
ttps://www.uptodate.com/contents/colistin-colistimethate-drug-information/a=
bstract-text/26801512/pubmed">26801512</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-21555763">
                 =20
                     <a name=3D"21555763"></a>Garonzik SM, Li J, Thamlikitk=
ul V, et al. Population pharmacokinetics of colistin methanesulfonate and f=
ormed colistin in critically ill patients from a multicenter study provide =
dosing suggestions for various categories of patients. <i>Antimicrob Agents=
 Chemother</i>. 2011;55(7):3284-3294.<span class=3D"pubmed-id"> [PubMed <a =
id=3D"21555763" target=3D"_blank" href=3D"https://www.uptodate.com/contents=
/colistin-colistimethate-drug-information/abstract-text/21555763/pubmed">21=
555763</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34469706">
                 =20
                     <a name=3D"34469706"></a>Goss CH, Heltshe SL, West NE,=
 et al; STOP2 Investigators. A randomized clinical trial of antimicrobial d=
uration for cystic fibrosis pulmonary exacerbation treatment. <i>Am J Respi=
r Crit Care Med</i>. 2021;204(11):1295-1305. doi:10.1164/rccm.202102-0461OC=
<span class=3D"pubmed-id"> [PubMed <a id=3D"34469706" target=3D"_blank" hre=
f=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informa=
tion/abstract-text/34469706/pubmed">34469706</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28614995">
                 =20
                     <a name=3D"28614995"></a>Greenwood J, Schwarz C, Somme=
rwerck U, et al. Ease of use of tobramycin inhalation powder compared with =
nebulized tobramycin and colistimethate sodium: a crossover study in cystic=
 fibrosis patients with pulmonary <i>Pseudomonas aeruginosa</i> infection. =
<i>Ther Adv Respir Dis</i>. 2017;11(7):249-260. doi:10.1177/175346581771059=
6<span class=3D"pubmed-id"> [PubMed <a id=3D"28614995" target=3D"_blank" hr=
ef=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inform=
ation/abstract-text/28614995/pubmed">28614995</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-21292654">
                 =20
                     <a name=3D"21292654"></a>Gupta K, Hooton TM, Naber KG,=
 et al; Infectious Diseases Society of America; European Society for Microb=
iology and Infectious Diseases. International clinical practice guidelines =
for the treatment of acute uncomplicated cystitis and pyelonephritis in wom=
en: a 2010 update by the Infectious Diseases Society of America and the Eur=
opean Society for Microbiology and Infectious Diseases. <i>Clin Infect Dis<=
/i>. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257<span class=3D"pubmed-id">=
 [PubMed <a id=3D"21292654" target=3D"_blank" href=3D"https://www.uptodate.=
com/contents/colistin-colistimethate-drug-information/abstract-text/2129265=
4/pubmed">21292654</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Gupta.1">
                 =20
                     <a name=3D"Gupta.1"></a>Gupta K. Acute complicated uri=
nary tract infection (including pyelonephritis) in adults. Post TW, ed. UpT=
oDate. Waltham, MA: UpToDate Inc. <a target=3D"_blank" href=3D"http://www.u=
ptodate.com/">http://www.uptodate.com</a>. Accessed September 5, 2023.</div=
>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Hasbun.1">
                 =20
                     <a name=3D"Hasbun.1"></a>Hasbun R. Treatment of bacter=
ial meningitis caused by specific pathogens in adults. Post TW, ed. UpToDat=
e. Waltham, MA: UpToDate Inc. <a target=3D"_blank" href=3D"http://www.uptod=
ate.com/">http://www.uptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24625200">
                 =20
                     <a name=3D"24625200"></a>Haworth CS, Foweraker JE, Wil=
kinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiect=
asis and chronic <i>Pseudomonas aeruginosa</i> infection. <i>Am J Respir Cr=
it Care Med</i>. 2014;189(8):975-982.<span class=3D"pubmed-id"> [PubMed <a =
id=3D"24625200" target=3D"_blank" href=3D"https://www.uptodate.com/contents=
/colistin-colistimethate-drug-information/abstract-text/24625200/pubmed">24=
625200</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23070159">
                 =20
                     <a name=3D"23070159"></a>Healan AM, Gray W, Fuchs EJ, =
Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqu=
eous solution. <i>Antimicrob Agents Chemother</i>. 2012;56(12):6432-6433<sp=
an class=3D"pubmed-id"> [PubMed <a id=3D"23070159" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/23070159/pubmed">23070159</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34738022">
                 =20
                     <a name=3D"34738022"></a>Heil EL, Bork JT, Abbo LM, et=
 al. Optimizing the management of uncomplicated gram-negative bloodstream i=
nfections: consensus guidance using a modified delphi process. <i>Open Foru=
m Infect Dis</i>. 2021;8(10):ofab434. doi:10.1093/ofid/ofab434<span class=
=3D"pubmed-id"> [PubMed <a id=3D"34738022" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/34738022/pubmed">34738022</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19397464">
                 =20
                     <a name=3D"19397464"></a>Heintz BH, Matzke GR, Dager W=
E. Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adu=
lt Patients Receiving Continuous Renal Replacement Therapy or Intermittent =
Hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=3D"pub=
med-id"> [PubMed <a id=3D"19397464" target=3D"_blank" href=3D"https://www.u=
ptodate.com/contents/colistin-colistimethate-drug-information/abstract-text=
/19397464/pubmed">19397464</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-29743769">
                 =20
                     <a name=3D"29743769"></a>Hiremath P, Rangappa P, Jacob=
 I, Rao K. Cerebrospinal fluid lactate as a prognostic indicator in postneu=
rosurgical bacterial meningitis and use of intrathecal colistin. <i>Indian =
J Crit Care Med</i>. 2018;22(4):297-299. doi:10.4103/ijccm.IJCCM_418_17<spa=
n class=3D"pubmed-id"> [PubMed <a id=3D"29743769" target=3D"_blank" href=3D=
"https://www.uptodate.com/contents/colistin-colistimethate-drug-information=
/abstract-text/29743769/pubmed">29743769</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-12358344">
                 =20
                     <a name=3D"12358344"></a>Hodson ME, Gallagher CG, Gova=
n JR. A randomised clinical trial of nebulised tobramycin or colistin in cy=
stic fibrosis. <i>Eur Respir J</i>. 2002;20(3):658-664. doi:10.1183/0903193=
6.02.00248102<span class=3D"pubmed-id"> [PubMed <a id=3D"12358344" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/12358344/pubmed">12358344</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26113262">
                 =20
                     <a name=3D"26113262"></a>Honore PM, Jacobs R, Hendrick=
x I, De Waele E, De Regt J, Spapen HD.. Nebulized colistin for treatment of=
 ventilator-associated pneumonia caused by multidrug-resistant Gram-negativ=
e bacteria: we still need to straighten out the dose! <i>Crit Care</i>. 201=
5;19:265.<span class=3D"pubmed-id"> [PubMed <a id=3D"26113262" target=3D"_b=
lank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dru=
g-information/abstract-text/26113262/pubmed">26113262</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28128096">
                 =20
                     <a name=3D"28128096"></a>Horcajada JP, Sorl=C3=AD L, L=
uque S, et al. Validation of a colistin plasma concentration breakpoint as =
a predictor of nephrotoxicity in patients treated with colistin methanesulf=
onate.<i> Int J Antimicrob Agents.</i> 2016;48(6):725-727. doi:10.1016/j.ij=
antimicag.2016.08.020<span class=3D"pubmed-id"> [PubMed <a id=3D"28128096" =
target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colist=
imethate-drug-information/abstract-text/28128096/pubmed">28128096</a>]</spa=
n>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24501388">
                 =20
                     <a name=3D"24501388"></a>Hsu AJ, Tamma PD. Treatment o=
f multidrug-resistant Gram-negative infections in children. <i>Clin Infect =
Dis</i>. 2014;58(10):1439-1448. doi:10.1093/cid/ciu069<span class=3D"pubmed=
-id"> [PubMed <a id=3D"24501388" target=3D"_blank" href=3D"https://www.upto=
date.com/contents/colistin-colistimethate-drug-information/abstract-text/24=
501388/pubmed">24501388</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-32892635">
                 =20
                     <a name=3D"32892635"></a>Hussain K, Salat MS, Ambreen =
G, et al. Intravenous vs intravenous plus aerosolized colistin for treatmen=
t of ventilator-associated pneumonia - a matched case-control study in neon=
ates. <i>Expert Opin Drug Saf</i>. 2020;19(12):1641-1649. doi:10.1080/14740=
338.2020.1819980<span class=3D"pubmed-id"> [PubMed <a id=3D"32892635" targe=
t=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimeth=
ate-drug-information/abstract-text/32892635/pubmed">32892635</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33553063">
                 =20
                     <a name=3D"33553063"></a>Hussain K, Sohail Salat M, Am=
breen G, Iqbal J. Neurodevelopment outcome of neonates treated with intrave=
ntricular colistin for ventriculitis caused by multiple drug-resistant path=
ogens-a case series. <i>Front Pediatr</i>. 2021;8:582375. doi:10.3389/fped.=
2020.582375<span class=3D"pubmed-id"> [PubMed <a id=3D"33553063" target=3D"=
_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-d=
rug-information/abstract-text/33553063/pubmed">33553063</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-30073562">
                 =20
                     <a name=3D"30073562"></a>Ilhan O, Bor M, Ozdemir SA, A=
kbay S, Ozer EA. Efficacy and safety of intravenous colistin in very low bi=
rth weight preterm infants. <i>Paediatr Drugs</i>. 2018;20(5):475-481. doi:=
10.1007/s40272-018-0301-5<span class=3D"pubmed-id"> [PubMed <a id=3D"300735=
62" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-co=
listimethate-drug-information/abstract-text/30073562/pubmed">30073562</a>]<=
/span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22687507">
                 =20
                     <a name=3D"22687507"></a>Imberti R, Cusato M, Accetta =
G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intrave=
ntricular administration of colistin methanesulfonate. <i>Antimicrob Agents=
 Chemother</i>. 2012;56(8):4416-4421. doi:10.1128/AAC.00231-12<span class=
=3D"pubmed-id"> [PubMed <a id=3D"22687507" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/22687507/pubmed">22687507</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20119725">
                 =20
                     <a name=3D"20119725"></a>Iosifidis E, Antachopoulos C,=
 Ioannidou M, et al. Colistin Administration to Pediatric and Neonatal Pati=
ents. <i>Eur J Pediatr</i>, 2010;169(7):867-874.<span class=3D"pubmed-id"> =
[PubMed <a id=3D"20119725" target=3D"_blank" href=3D"https://www.uptodate.c=
om/contents/colistin-colistimethate-drug-information/abstract-text/20119725=
/pubmed">20119725</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28501490">
                 =20
                     <a name=3D"28501490"></a>=C4=B0pek MS, Aktar F, Okur N=
, Celik M, Ozbek E. Colistin use in critically ill neonates: A case-control=
 study. <i>Pediatr Neonatol</i>. 2017;58(6):490-496. doi:10.1016/j.pedneo.2=
016.10.002<span class=3D"pubmed-id"> [PubMed <a id=3D"28501490" target=3D"_=
blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dr=
ug-information/abstract-text/28501490/pubmed">28501490</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-3301785">
                 =20
                     <a name=3D"3301785"></a>Jensen T, Pederson SS, Garne S=
, et al. Colistin Inhalation Therapy in Cystic Fibrosis Patients With Chron=
ic <i>Pseudomonas aeruginosa</i> Lung Infection. <i>J Antimicrob Chemother<=
/i>. 1987;19(6):831-838.<span class=3D"pubmed-id"> [PubMed <a id=3D"3301785=
" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-coli=
stimethate-drug-information/abstract-text/3301785/pubmed">3301785</a>]</spa=
n>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25698772">
                 =20
                     <a name=3D"25698772"></a>Jitmuang A, Nation RL, Kooman=
achai P, et al. Extracorporeal clearance of colistin methanesulphonate and =
formed colistin in end-stage renal disease patients receiving intermittent =
haemodialysis: implications for dosing. <i>J Antimicrob Chemother</i>. 2015=
;70(6):1804-1811. doi:10.1093/jac/dkv031<span class=3D"pubmed-id"> [PubMed =
<a id=3D"25698772" target=3D"_blank" href=3D"https://www.uptodate.com/conte=
nts/colistin-colistimethate-drug-information/abstract-text/25698772/pubmed"=
>25698772</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-27418577">
                 =20
                     <a name=3D"27418577"></a>Kalil AC, Metersky ML, Klompa=
s M, et al. Management of adults with hospital-acquired and ventilator-asso=
ciated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Disea=
ses Society of America and the American Thoracic Society. <i>Clin Infect Di=
s</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class=3D"pubmed-id"=
> [PubMed <a id=3D"27418577" target=3D"_blank" href=3D"https://www.uptodate=
.com/contents/colistin-colistimethate-drug-information/abstract-text/274185=
77/pubmed">27418577</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Kanafani.1">
                 =20
                     <a name=3D"Kanafani.1"></a>Kanafani ZA. Acinetobacter =
infection: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: Up=
ToDate Inc. <a target=3D"_blank" href=3D"http://www.uptodate.com/">http://w=
ww.uptodate.com</a>. Accessed September 5, 2023.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-32115388">
                 =20
                     <a name=3D"32115388"></a>Kapnadak SG, Dimango E, Hadji=
liadis D, et al. Cystic Fibrosis Foundation consensus guidelines for the ca=
re of individuals with advanced cystic fibrosis lung disease. <i>J Cyst Fib=
ros</i>. 2020;19(3):344-354. doi:10.1016/j.jcf.2020.02.015<span class=3D"pu=
bmed-id"> [PubMed <a id=3D"32115388" target=3D"_blank" href=3D"https://www.=
uptodate.com/contents/colistin-colistimethate-drug-information/abstract-tex=
t/32115388/pubmed">32115388</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23689704">
                 =20
                     <a name=3D"23689704"></a>Kapoor K, Jajoo M, Dublish S,=
 Dabas V, Gupta S, Manchanda V. Intravenous colistin for multidrug-resistan=
t gram-negative infections in critically ill pediatric patients. <i>Pediatr=
 Crit Care Med</i>. 2013;14(6):e268-e272. doi:10.1097/PCC.0b013e31828a740f<=
span class=3D"pubmed-id"> [PubMed <a id=3D"23689704" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/23689704/pubmed">23689704</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23507414">
                 =20
                     <a name=3D"23507414"></a>Karaiskos I, Galani L, Baziak=
a F, Giamarellou H. Intraventricular and intrathecal colistin as the last t=
herapeutic resort for the treatment of multidrug-resistant and extensively =
drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis:=
 a literature review. <i>Int J Antimicrob Agents</i>. 2013;41(6):499-508.<s=
pan class=3D"pubmed-id"> [PubMed <a id=3D"23507414" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/23507414/pubmed">23507414</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-27474468">
                 =20
                     <a name=3D"27474468"></a>Karaiskos I, Friberg LE, Gala=
ni L, et al. Challenge for higher colistin dosage in critically ill patient=
s receiving continuous venovenous haemodiafiltration. <i>Int J Antimicrob A=
gents</i>. 2016;48(3):337-341. doi:10.1016/j.ijantimicag.2016.06.008<span c=
lass=3D"pubmed-id"> [PubMed <a id=3D"27474468" target=3D"_blank" href=3D"ht=
tps://www.uptodate.com/contents/colistin-colistimethate-drug-information/ab=
stract-text/27474468/pubmed">27474468</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23147733">
                 =20
                     <a name=3D"23147733"></a>Karvanen M, Plachouras D, Fri=
berg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in =
critically ill patients receiving continuous venovenous hemodiafiltration. =
<i>Antimicrob Agents Chemother</i>. 2013;57(1):668-671. doi:10.1128/AAC.009=
85-12<span class=3D"pubmed-id"> [PubMed <a id=3D"23147733" target=3D"_blank=
" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-in=
formation/abstract-text/23147733/pubmed">23147733</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25461655">
                 =20
                     <a name=3D"25461655"></a>Kassamali Z, Jain R, Danziger=
 LH. An update on the arsenal for multidrug-resistant Acinetobacter infecti=
ons: polymyxin antibiotics. <i>Int J Infect Dis</i>. 2015;30:125-132. doi:1=
0.1016/j.ijid.2014.10.014<span class=3D"pubmed-id"> [PubMed <a id=3D"254616=
55" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-co=
listimethate-drug-information/abstract-text/25461655/pubmed">25461655</a>]<=
/span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23728146">
                 =20
                     <a name=3D"23728146"></a>Kassamali Z, Rotschafer JC, J=
ones RN, Prince RA, Danziger LH. Polymyxins: wisdom does not always come wi=
th age. <i>Clin Infect Dis</i>. 2013;57(6):877-883. doi:10.1093/cid/cit367<=
span class=3D"pubmed-id"> [PubMed <a id=3D"23728146" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/23728146/pubmed">23728146</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-16145177">
                 =20
                     <a name=3D"16145177"></a>Katragkou A, Roilides E. Succ=
essful Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Cent=
ral Nervous System Infections With Colistin. <i>J Clin Microbiol</i>. 2005;=
43(9):4916-4917.<span class=3D"pubmed-id"> [PubMed <a id=3D"16145177" targe=
t=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimeth=
ate-drug-information/abstract-text/16145177/pubmed">16145177</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-5448745">
                 =20
                     <a name=3D"5448745"></a>Koch-Weser J, Sidel VW, Federm=
an EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimeth=
ate. Manifestations and specific reaction rates during 317 courses of thera=
py. <i>Ann Intern Med</i>. 1970;72(6):857-868.<span class=3D"pubmed-id"> [P=
ubMed <a id=3D"5448745" target=3D"_blank" href=3D"https://www.uptodate.com/=
contents/colistin-colistimethate-drug-information/abstract-text/5448745/pub=
med">5448745</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25278817">
                 =20
                     <a name=3D"25278817"></a>Koerner-Rettberg C, Ballman M=
. Colistimethate sodium for the treatment of chronic pulmonary infection in=
 cystic fibrosis: an evidence-based review of its place in therapy. <i>Core=
 Evid</i>. 2014;9:99-112.<span class=3D"pubmed-id"> [PubMed <a id=3D"252788=
17" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-co=
listimethate-drug-information/abstract-text/25278817/pubmed">25278817</a>]<=
/span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24189256">
                 =20
                     <a name=3D"24189256"></a>Koomanachai P, Landersdorfer =
CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed=
 colistin in end-stage renal disease patients receiving continuous ambulato=
ry peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 2014;58(1):440-=
446.<span class=3D"pubmed-id"> [PubMed <a id=3D"24189256" target=3D"_blank"=
 href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inf=
ormation/abstract-text/24189256/pubmed">24189256</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25643276">
                 =20
                     <a name=3D"25643276"></a>Landersdorfer CB, Nation RL. =
Colistin: How should it be dosed for the critically ill? <i>Semin Respir Cr=
it Care Med</i>. 2015;36:126-135.<span class=3D"pubmed-id"> [PubMed <a id=
=3D"25643276" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/25643276/pubmed">2564=
3276</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19821321">
                 =20
                     <a name=3D"19821321"></a>Langton Hewer SC, Smyth AR. A=
ntibiotic strategies for eradicating <i>Pseudomonas aeruginosa</i> in peopl=
e with cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD00419=
7.<span class=3D"pubmed-id"> [PubMed <a id=3D"19821321" target=3D"_blank" h=
ref=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-infor=
mation/abstract-text/19821321/pubmed">19821321</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28440853">
                 =20
                     <a name=3D"28440853"></a>Langton Hewer SC, Smyth AR. A=
ntibiotic strategies for eradicating Pseudomonas aeruginosa in people with =
cystic fibrosis. <i>Cochrane Database Syst Rev</i>. 2017;4(4):CD004197. doi=
:10.1002/14651858.CD004197.pub5<span class=3D"pubmed-id"> [PubMed <a id=3D"=
28440853" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colis=
tin-colistimethate-drug-information/abstract-text/28440853/pubmed">28440853=
</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34806975">
                 =20
                     <a name=3D"34806975"></a>Langton Hewer SC, Smyth AR, B=
rown M, et al. Intravenous or oral antibiotic treatment in adults and child=
ren with cystic fibrosis and <i>Pseudomonas aeruginosa</i> infection: the T=
ORPEDO-CF RCT. <i>Health Technol Assess</i>. 2021;25(65):1-128. doi:10.3310=
/hta25650<span class=3D"pubmed-id"> [PubMed <a id=3D"34806975" target=3D"_b=
lank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dru=
g-information/abstract-text/34806975/pubmed">34806975</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20500046">
                 =20
                     <a name=3D"20500046"></a>Le J, Ashley ED, Neuhauser MM=
, et al. Consensus summary of aerosolized antimicrobial agents: application=
 of guideline criteria. Insights from the Society of Infectious Diseases Ph=
armacists. <i>Pharmacotherapy</i>. 2010;30(6):562-584. doi:10.1592/phco.30.=
6.562<span class=3D"pubmed-id"> [PubMed <a id=3D"20500046" target=3D"_blank=
" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-in=
formation/abstract-text/20500046/pubmed">20500046</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-9762785">
                 =20
                     <a name=3D"9762785"></a>Ledson MJ, Gallagher MJ, Cowpe=
rthwaite C, Convery RP, Walshaw MJ. Four years' experience of intravenous c=
olomycin in an adult cystic fibrosis unit. <i>Eur Respir J</i>. 1998;12(3):=
592-594.<span class=3D"pubmed-id"> [PubMed <a id=3D"9762785" target=3D"_bla=
nk" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-=
information/abstract-text/9762785/pubmed">9762785</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20500046">
                 =20
                     <a name=3D"20500046"></a>Le J, Ashley ED, Neuhauser MM=
, et al. Consensus Summary of Aerosolized Antimicrobial Agents: Application=
 of Guideline Criteria. <i>Pharmacotherapy</i>. 2010;30(6):562-584.<span cl=
ass=3D"pubmed-id"> [PubMed <a id=3D"20500046" target=3D"_blank" href=3D"htt=
ps://www.uptodate.com/contents/colistin-colistimethate-drug-information/abs=
tract-text/20500046/pubmed">20500046</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-14585859">
                 =20
                     <a name=3D"14585859"></a>Li J, Coulthard K, Milne R, e=
t al. Steady-state pharmacokinetics of intravenous colistin methanesulphona=
te in patients with cystic fibrosis. <i>J Antimicrob Chemother</i>. 2003;52=
(6):987-992.<span class=3D"pubmed-id"> [PubMed <a id=3D"14585859" target=3D=
"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-=
drug-information/abstract-text/14585859/pubmed">14585859</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-16931410">
                 =20
                     <a name=3D"16931410"></a>Li J, Nation RL, Turnidge JD,=
 et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-n=
egative bacterial infections. <i>Lancet Infect Dis</i>. 2006;6(9):589-601.<=
span class=3D"pubmed-id"> [PubMed <a id=3D"16931410" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/16931410/pubmed">16931410</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-16251342">
                 =20
                     <a name=3D"16251342"></a>Li J, Rayner CR, Nation RL, e=
t al. Pharmacokinetics of Colistin Methanesulfonate and Colistin in a Criti=
cally Ill Patient Receiving Continuous Venovenous Hemodiafiltration. <i>Ant=
imicrob Agents Chemother</i>,.2005;49(11):4814-4815.<span class=3D"pubmed-i=
d"> [PubMed <a id=3D"16251342" target=3D"_blank" href=3D"https://www.uptoda=
te.com/contents/colistin-colistimethate-drug-information/abstract-text/1625=
1342/pubmed">16251342</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-21114395">
                 =20
                     <a name=3D"21114395"></a>Lim LM, Ly N, Anderson D, et =
al. Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynam=
ics, and Dosing. <i>Pharmacotherapy</i>. 2010;30(12):1279-1291.<span class=
=3D"pubmed-id"> [PubMed <a id=3D"21114395" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/21114395/pubmed">21114395</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-35678460">
                 =20
                     <a name=3D"35678460"></a>Lipp MA, Crass RL, Fitzgerald=
 LJ, et al. Acute kidney injury in cystic fibrosis patients treated with in=
travenous colistimethate sodium or tobramycin. <i>J Antimicrob Chemother</i=
>. 2022;77(9):2516-2521. doi:10.1093/jac/dkac187<span class=3D"pubmed-id"> =
[PubMed <a id=3D"35678460" target=3D"_blank" href=3D"https://www.uptodate.c=
om/contents/colistin-colistimethate-drug-information/abstract-text/35678460=
/pubmed">35678460</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23132092">
                 =20
                     <a name=3D"23132092"></a>Lu Q, Luo R, Bodin L, et al. =
Efficacy of High-Dose Nebulized Colistin In Ventilator-Associated Pneumonia=
 Caused By Multidrug-Resistant <i>Pseudomonas aeruginosa</i> and <i>Acineto=
bacter baumannii</i>. <i>Anesthesiology</i>. 2012;117(6):1335-1347.<span cl=
ass=3D"pubmed-id"> [PubMed <a id=3D"23132092" target=3D"_blank" href=3D"htt=
ps://www.uptodate.com/contents/colistin-colistimethate-drug-information/abs=
tract-text/23132092/pubmed">23132092</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19704130">
                 =20
                     <a name=3D"19704130"></a>Markantonis SL, Markou N, Fou=
steri M, et al. Penetration of colistin into cerebrospinal fluid. <i>Antimi=
crob Agents Chemother</i>. 2009;53(11):4907=E2=80=904910. doi:10.1128/AAC.0=
0345-09<span class=3D"pubmed-id"> [PubMed <a id=3D"19704130" target=3D"_bla=
nk" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-=
information/abstract-text/19704130/pubmed">19704130</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-18343250">
                 =20
                     <a name=3D"18343250"></a>Markou N, Markantonis SL, Dim=
itrakis E, et al. Colistin serum concentrations after intravenous administr=
ation in critically ill patients with serious multidrug-resistant, gram-neg=
ative bacilli infections: a prospective, open-label, uncontrolled study. <i=
>Clin Ther</i>. 2008;30(1):143-151. doi:10.1016/j.clinthera.2008.01.015<spa=
n class=3D"pubmed-id"> [PubMed <a id=3D"18343250" target=3D"_blank" href=3D=
"https://www.uptodate.com/contents/colistin-colistimethate-drug-information=
/abstract-text/18343250/pubmed">18343250</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25459739">
                 =20
                     <a name=3D"25459739"></a>Maskin LP, Setten M, Rodrigue=
z PO, et al. Inhaled colistimethate sodium in ventilator-associated tracheo=
bronchitis due to multidrug-resistant Gram-negative bacteria. <i>Int J Anti=
microb Agents</i>. 2015;45(2):199-200.<span class=3D"pubmed-id"> [PubMed <a=
 id=3D"25459739" target=3D"_blank" href=3D"https://www.uptodate.com/content=
s/colistin-colistimethate-drug-information/abstract-text/25459739/pubmed">2=
5459739</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28085573">
                 =20
                     <a name=3D"28085573"></a>Mazuski JE, Tessier JM, May A=
K, et al. The Surgical Infection Society revised guidelines on the manageme=
nt of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1=
-76. doi:10.1089/sur.2016.261<span class=3D"pubmed-id"> [PubMed <a id=3D"28=
085573" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colisti=
n-colistimethate-drug-information/abstract-text/28085573/pubmed">28085573</=
a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-18046039">
                 =20
                     <a name=3D"18046039"></a>McCoy KS. Compounded colistim=
ethate as possible cause of fatal acute respiratory distress syndrome. <i>N=
 Engl J Med</i>. 2007;357(22):2310-2311.<span class=3D"pubmed-id"> [PubMed =
<a id=3D"18046039" target=3D"_blank" href=3D"https://www.uptodate.com/conte=
nts/colistin-colistimethate-drug-information/abstract-text/18046039/pubmed"=
>18046039</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-18060758">
                 =20
                     <a name=3D"18060758"></a>Michalopoulos A, Fotakis D, V=
irtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilato=
r-associate pneumonia due to multidrug-resistant Gram-negative bacteria: a =
prospective study [published online ahead of print December 3, 2007]. <i>Re=
spir Med</i>. 2008;102(3):407-412.<span class=3D"pubmed-id"> [PubMed <a id=
=3D"18060758" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/18060758/pubmed">1806=
0758</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23540878">
                 =20
                     <a name=3D"23540878"></a>Mogayzel PJ Jr, Naureckas ET,=
 Robinson KA, et al; Pulmonary Clinical Practice Guidelines Committee. Cyst=
ic fibrosis pulmonary guidelines. Chronic medications for maintenance of lu=
ng health. <i>Am J Respir Crit Care Med</i>. 2013;187(7):680-689. doi:10.11=
64/rccm.201207-1160oe<span class=3D"pubmed-id"> [PubMed <a id=3D"23540878" =
target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colist=
imethate-drug-information/abstract-text/23540878/pubmed">23540878</a>]</spa=
n>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Moiraghi.1">
                 =20
                     <a name=3D"Moiraghi.1"></a>Moiraghi A, Moiraghi P. Col=
istin in Organic Fluids. In, Herold M, Gabriel Z, eds. <i>Antibiotics: Adva=
nces in Research, Production and Clinical Use; Proceedings of the Congress =
on Antibiotics Held in Prague, 15-19 June, 1964</i>. London, Butterworths, =
1966;188-192.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-31469781">
                 =20
                     <a name=3D"31469781"></a>Nakwan N, Chokephaibulkit K, =
Imberti R. The use of colistin for the treatment of multidrug-resistant gra=
m-negative infections in neonates and infants: a review of the literature. =
<i>Pediatr Infect Dis J</i>. 2019;38(11):1107-1112. doi:10.1097/INF.0000000=
000002448<span class=3D"pubmed-id"> [PubMed <a id=3D"31469781" target=3D"_b=
lank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dru=
g-information/abstract-text/31469781/pubmed">31469781</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26065861">
                 =20
                     <a name=3D"26065861"></a>Nakwan N, Lertpichaluk P, Cho=
kephaibulkit K, Villani P, Regazzi M, Imberti R. Pulmonary and systemic pha=
rmacokinetics of colistin following a single dose of nebulized colistimetha=
te in mechanically ventilated neonates. <i>Pediatr Infect Dis J</i>. 2015;3=
4(9):961-963. doi:10.1097/INF.0000000000000775<span class=3D"pubmed-id"> [P=
ubMed <a id=3D"26065861" target=3D"_blank" href=3D"https://www.uptodate.com=
/contents/colistin-colistimethate-drug-information/abstract-text/26065861/p=
ubmed">26065861</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-27276179">
                 =20
                     <a name=3D"27276179"></a>Nakwan N, Usaha S, Chokephaib=
ulkit K, Villani P, Regazzi M, Imberti R. Pharmacokinetics of colistin foll=
owing a single dose of intravenous colistimethate sodium in critically ill =
neonates. <i>Pediatr Infect Dis J</i>. 2016;35(11):1211-1214. doi:10.1097/I=
NF.0000000000001263<span class=3D"pubmed-id"> [PubMed <a id=3D"27276179" ta=
rget=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistim=
ethate-drug-information/abstract-text/27276179/pubmed">27276179</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20812247">
                 =20
                     <a name=3D"20812247"></a>Nakwan N, Wannaro J, Thongmak=
 T, et al. Safety in Treatment of Ventilator-Associated Pneumonia Due to Ex=
tensive Drug-Resistant <i>Acinetobacter baumannii</i> With Aerosolized Coli=
stin in Neonates: A Preliminary Report. <i>Pediatr Pulmonol</i>. 2011;46(1)=
:60-66.<span class=3D"pubmed-id"> [PubMed <a id=3D"20812247" target=3D"_bla=
nk" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-=
information/abstract-text/20812247/pubmed">20812247</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26607424">
                 =20
                     <a name=3D"26607424"></a>Nation RL, Garonzik SM, Li J,=
 et al. Updated US and European dose recommendations for intravenous colist=
in: how do they perform? <i>Clin Infect Dis.</i> 2016;62(5):552-558.<span c=
lass=3D"pubmed-id"> [PubMed <a id=3D"26607424" target=3D"_blank" href=3D"ht=
tps://www.uptodate.com/contents/colistin-colistimethate-drug-information/ab=
stract-text/26607424/pubmed">26607424</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28011614">
                 =20
                     <a name=3D"28011614"></a>Nation RL, Garonzik SM, Thaml=
ikitkul V, et al. Dosing guidance for intravenous colistin in critically-il=
l patients. <i>Clin Infect Dis</i>. 2017;64(5):565-571. doi:10.1093/cid/ciw=
839<span class=3D"pubmed-id"> [PubMed <a id=3D"28011614" target=3D"_blank" =
href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-info=
rmation/abstract-text/28011614/pubmed">28011614</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24107410">
                 =20
                     <a name=3D"24107410"></a>Nation RL, Li J, Cars O, et a=
l. Consistent global approach on reporting of colistin doses to promote saf=
e and effective use. <i>Clin Infect Dis.</i> 2014;58(1):139-141.<span class=
=3D"pubmed-id"> [PubMed <a id=3D"24107410" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/24107410/pubmed">24107410</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-16916866">
                 =20
                     <a name=3D"16916866"></a>Ng J, Gosbell IB, Kelly JA, B=
oyle MJ, Ferguson JK. Cure of multiresistant Acinetobacter baumannii centra=
l nervous system infections with intraventricular or intrathecal colistin: =
case series and literature review. <i>J Antimicrob Chemother</i>. 2006;58(5=
):1078-1081.<span class=3D"pubmed-id"> [PubMed <a id=3D"16916866" target=3D=
"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-=
drug-information/abstract-text/16916866/pubmed">16916866</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34588142">
                 =20
                     <a name=3D"34588142"></a>Nicholson TT, Smith A, McKone=
 EF, Gallagher CG. Duration of intravenous antibiotic treatment for acute e=
xacerbations of cystic fibrosis: A systematic review. <i>J Cyst Fibros</i>.=
 2022;21(4):562-573. doi:10.1016/j.jcf.2021.08.017<span class=3D"pubmed-id"=
> [PubMed <a id=3D"34588142" target=3D"_blank" href=3D"https://www.uptodate=
.com/contents/colistin-colistimethate-drug-information/abstract-text/345881=
42/pubmed">34588142</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19733029">
                 =20
                     <a name=3D"19733029"></a>Oliveira MS, Prado GV, Costa =
SF, Grinbaum RS, Levin AS. Polymyxin B and colistimethate are comparable as=
 to efficacy and renal toxicity. <i>Diagn Microbiol Infect Dis</i>. 2009;65=
(4):431-434.<span class=3D"pubmed-id"> [PubMed <a id=3D"19733029" target=3D=
"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-=
drug-information/abstract-text/19733029/pubmed">19733029</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-30722017">
                 =20
                     <a name=3D"30722017"></a>Ooi MH, Ngu SJ, Chor YK, Li J=
, Landersdorfer CB, Nation RL. Population pharmacokinetics of intravenous c=
olistin in pediatric patients: implications for the selection of dosage reg=
imens. <i>Clin Infect Dis</i>. 2019;69(11):1962-1968. doi:10.1093/cid/ciz06=
7<span class=3D"pubmed-id"> [PubMed <a id=3D"30722017" target=3D"_blank" hr=
ef=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inform=
ation/abstract-text/30722017/pubmed">30722017</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20358244">
                 =20
                     <a name=3D"20358244"></a>Ozdemir H, Tapisiz A, Cift=C3=
=A7i E, et al. Successful treatment of three children with post-neurosurgic=
al multidrug-resistant <i>Acinetobacter baumannii</i> meningitis. <i>Infect=
ion</i>. 2010;38(3):241-244.<span class=3D"pubmed-id"> [PubMed <a id=3D"203=
58244" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin=
-colistimethate-drug-information/abstract-text/20358244/pubmed">20358244</a=
>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19433570">
                 =20
                     <a name=3D"19433570"></a>Plachouras D, Karvanen M, Fri=
berg LE, et al. Population pharmacokinetic analysis of colistin methanesulf=
onate and colistin after intravenous administration in critically ill patie=
nts with infections caused by gram-negative bacteria. <i>Antimicrob Agents =
Chemother</i>. 2009;53(8):3430-3436.<span class=3D"pubmed-id"> [PubMed <a i=
d=3D"19433570" target=3D"_blank" href=3D"https://www.uptodate.com/contents/=
colistin-colistimethate-drug-information/abstract-text/19433570/pubmed">194=
33570</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25939411">
                 =20
                     <a name=3D"25939411"></a>Polat M, Kara SS, Tap=C4=B1s=
=C4=B1z A, Tezer H, Kalkan G, Dolgun A. Treatment of ventilator-associated =
pneumonia using intravenous colistin alone or in combination with inhaled c=
olistin in critically ill children. <i>Paediatr Drugs</i>. 2015;17(4):323-3=
30. doi:10.1007/s40272-015-0133-5<span class=3D"pubmed-id"> [PubMed <a id=
=3D"25939411" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/25939411/pubmed">2593=
9411</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28889110">
                 =20
                     <a name=3D"28889110"></a>Polverino E, Goeminne PC, McD=
onnell MJ, et al. European Respiratory Society guidelines for the managemen=
t of adult bronchiectasis. <i>Eur Respir J</i>. 2017;50(3):1700629. doi:10.=
1183/13993003.00629-2017<span class=3D"pubmed-id"> [PubMed <a id=3D"2888911=
0" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-col=
istimethate-drug-information/abstract-text/28889110/pubmed">28889110</a>]</=
span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-31033908">
                 =20
                     <a name=3D"31033908"></a>Pratheep R, Ray S, Mukhopadhy=
ay K, et al. First case report of intraventricular tigecycline in a neonate=
 with extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculit=
is. <i>Pediatr Infect Dis J</i>. 2019;38(8):e172-e174. doi:10.1097/INF.0000=
000000002348<span class=3D"pubmed-id"> [PubMed <a id=3D"31033908" target=3D=
"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-=
drug-information/abstract-text/31033908/pubmed">31033908</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22762867">
                 =20
                     <a name=3D"22762867"></a>Proesmans M, Vermeulen F, Bou=
langer L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for=
 eradication of <i>Pseudomonas aeruginosa</i> infection in children with cy=
stic fibrosis. <i>J Cyst Fibros</i>. 2013;12(1):29-34. doi:10.1016/j.jcf.20=
12.06.001<span class=3D"pubmed-id"> [PubMed <a id=3D"22762867" target=3D"_b=
lank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dru=
g-information/abstract-text/22762867/pubmed">22762867</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-15811909">
                 =20
                     <a name=3D"15811909"></a>Quinn AL, Parada JP, Belmares=
 J, et al. Intrathecal Colistin and Sterilization of Resistant <i>Pseudomon=
as aeruginosa</i> Shunt Infection. <i>Ann Pharmacother</i>. 2005;39(5):949-=
952.<span class=3D"pubmed-id"> [PubMed <a id=3D"15811909" target=3D"_blank"=
 href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inf=
ormation/abstract-text/15811909/pubmed">15811909</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24673698">
                 =20
                     <a name=3D"24673698"></a>Quon BS, Goss CH, Ramsey BW. =
Inhaled antibiotics for lower airway infections. <i>Ann Am Thorac Soc</i>. =
2014;11(3):425-434. doi:10.1513/AnnalsATS.201311-395FR<span class=3D"pubmed=
-id"> [PubMed <a id=3D"24673698" target=3D"_blank" href=3D"https://www.upto=
date.com/contents/colistin-colistimethate-drug-information/abstract-text/24=
673698/pubmed">24673698</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-33612816">
                 =20
                     <a name=3D"33612816"></a>Rasidin RSM, Suhaili Z, Moham=
ed AFS, Hod R, Neela V, Amin-Nordin S. Time-kill and post-antibiotic effect=
 of colistin at different static concentrations in in vitro Acinetobacter b=
aumannii. <i>Trop Biomed.</i> 2020;37(2):471-481.<span class=3D"pubmed-id">=
 [PubMed <a id=3D"33612816" target=3D"_blank" href=3D"https://www.uptodate.=
com/contents/colistin-colistimethate-drug-information/abstract-text/3361281=
6/pubmed">33612816</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20876621">
                 =20
                     <a name=3D"20876621"></a>Rattanaumpawan P, Lorsutthith=
am J, Ungprasert P, Angkasekwinai N, Thamlikitkul V. Randomized controlled =
trial of nebulized colistimethate sodium as adjunctive therapy of ventilato=
r-associated pneumonia caused by gram-negative bacteria. <i>J Antimicrob Ch=
emother</i>. 2010;65(12):2645-2649. doi:10.1093/jac/dkq360<span class=3D"pu=
bmed-id"> [PubMed <a id=3D"20876621" target=3D"_blank" href=3D"https://www.=
uptodate.com/contents/colistin-colistimethate-drug-information/abstract-tex=
t/20876621/pubmed">20876621</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-11402633">
                 =20
                     <a name=3D"11402633"></a>Reed MD, Stern RC, O'Riordan =
MA, et al. The Pharmacokinetics of Colistin in Patients With Cystic Fibrosi=
s. <i>J Clin Pharmacol</i>. 2001;41(6):645-654.<span class=3D"pubmed-id"> [=
PubMed <a id=3D"11402633" target=3D"_blank" href=3D"https://www.uptodate.co=
m/contents/colistin-colistimethate-drug-information/abstract-text/11402633/=
pubmed">11402633</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Manu.1">
                 =20
                     <a name=3D"Manu.1"></a>Refer to manufacturer's labelin=
g.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-27576543">
                 =20
                     <a name=3D"27576543"></a>Riethm=C3=BCller J, Herrmann =
G, Graepler-Mainka U, et al. Sequential inhalational tobramycin-colistin-co=
mbination in CF-patients with chronic <i>P. aeruginosa</i> colonization - a=
n observational study. <i>Cell Physiol Biochem</i>. 2016;39(3):1141-1151. d=
oi:10.1159/000447821<span class=3D"pubmed-id"> [PubMed <a id=3D"27576543" t=
arget=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colisti=
methate-drug-information/abstract-text/27576543/pubmed">27576543</a>]</span=
>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-18281693">
                 =20
                     <a name=3D"18281693"></a>Rodr=C3=ADguez Guardado A, Bl=
anco A, Asensi V, et al. Multidrug-resistant Acinetobacter meningitis in ne=
urosurgical patients with intraventricular catheters: assessment of differe=
nt treatments. <i>J Antimicrob Chemother</i>. 2008;61(4):908-913. doi:10.10=
93/jac/dkn018<span class=3D"pubmed-id"> [PubMed <a id=3D"18281693" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/18281693/pubmed">18281693</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-19436571">
                 =20
                     <a name=3D"19436571"></a>Sabuda DM, Laupland K, Pitout=
 J, et al. Utilization of Colistin for Treatment of Multidrug-Resistant <i>=
Pseudomonas aeruginosa</i>. <i>Can J Infect Dis Med Microbiol</i>. 2008;19(=
6):413-418.<span class=3D"pubmed-id"> [PubMed <a id=3D"19436571" target=3D"=
_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-d=
rug-information/abstract-text/19436571/pubmed">19436571</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-29361414">
                 =20
                     <a name=3D"29361414"></a>Sahbudak Bal Z, Kamit Can F, =
Yazici P, et al. The evaluation of safety and efficacy of colistin use in p=
ediatric intensive care unit: Results from two reference hospitals and revi=
ew of literature. <i>J Infect Chemother</i>. 2018;24(5):370-375. doi:10.101=
6/j.jiac.2017.12.017<span class=3D"pubmed-id"> [PubMed <a id=3D"29361414" t=
arget=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colisti=
methate-drug-information/abstract-text/29361414/pubmed">29361414</a>]</span=
>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34497678">
                 =20
                     <a name=3D"34497678"></a>Sari ND, Baltali S, Serin I, =
Antar V. Evaluation of intraventricular/intrathecal antimicrobial therapy i=
n the treatment of nosocomial meningitis caused by multidrug-resistant gram=
-negative bacteria after central nervous system surgery. <i>Can J Infect Di=
s Med Microbiol</i>. 2021;2021:9923015. doi:10.1155/2021/9923015<span class=
=3D"pubmed-id"> [PubMed <a id=3D"34497678" target=3D"_blank" href=3D"https:=
//www.uptodate.com/contents/colistin-colistimethate-drug-information/abstra=
ct-text/34497678/pubmed">34497678</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25992746">
                 =20
                     <a name=3D"25992746"></a>Sawyer RG, Claridge JA, Nathe=
ns AB, et al; STOP-IT Trial Investigators. Trial of short-course antimicrob=
ial therapy for intraabdominal infection. <i>N Engl J Med</i>. 2015;372(21)=
:1996-2005. doi:10.1056/NEJMoa1411162<span class=3D"pubmed-id"> [PubMed <a =
id=3D"25992746" target=3D"_blank" href=3D"https://www.uptodate.com/contents=
/colistin-colistimethate-drug-information/abstract-text/25992746/pubmed">25=
992746</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-26456474">
                 =20
                     <a name=3D"26456474"></a>Shofty B, Neuberger A, Naffaa=
 ME, et al. Intrathecal or intraventricular therapy for post-neurosurgical =
Gram-negative meningitis: matched cohort study. <i>Clin Microbiol Infect</i=
>. 2016;22(1):66-70. doi:10.1016/j.cmi.2015.09.023<span class=3D"pubmed-id"=
> [PubMed <a id=3D"26456474" target=3D"_blank" href=3D"https://www.uptodate=
.com/contents/colistin-colistimethate-drug-information/abstract-text/264564=
74/pubmed">26456474</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Simon.1">
                 =20
                     <a name=3D"Simon.1"></a>Simon RH. Cystic fibrosis: ant=
ibiotic therapy for pulmonary exacerbations. Post TW, ed. UpToDate. Waltham=
, MA: UpToDate Inc. <a target=3D"_blank" href=3D"http://www.uptodate.com/">=
http://www.uptodate.com</a>. Accessed September 5, 2023a.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Simon.2">
                 =20
                     <a name=3D"Simon.2"></a>Simon RH. Cystic fibrosis: Ant=
ibiotic therapy for chronic pulmonary infection. Post TW, ed. UpToDate. Wal=
tham, MA: UpToDate Inc. <a target=3D"_blank" href=3D"http://www.uptodate.co=
m/">http://www.uptodate.com</a>. Accessed October 4, 2023b.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23957376">
                 =20
                     <a name=3D"23957376"></a>Sorl=C3=AD L, Luque S, Grau S=
, et al. Trough colistin plasma level is an independent risk factor for nep=
hrotoxicity: a prospective observational cohort study. <i>BMC Infect Dis.</=
i> 2013;13:380. doi:10.1186/1471-2334-13-380<span class=3D"pubmed-id"> [Pub=
Med <a id=3D"23957376" target=3D"_blank" href=3D"https://www.uptodate.com/c=
ontents/colistin-colistimethate-drug-information/abstract-text/23957376/pub=
med">23957376</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-17547727">
                 =20
                     <a name=3D"17547727"></a>Steinfort DP, Steinfort C. Ef=
fect of Long-Term Nebulized Colistin on Lung Function and Quality of Life i=
n Patients With Chronic Bronchial Sepsis. <i>Intern Med J</i>. 2007;37(7):4=
95-498.<span class=3D"pubmed-id"> [PubMed <a id=3D"17547727" target=3D"_bla=
nk" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-=
information/abstract-text/17547727/pubmed">17547727</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24947530">
                 =20
                     <a name=3D"24947530"></a>Stevens DL, Bisno AL, Chamber=
s HF, et al. Practice guidelines for the diagnosis and management of skin a=
nd soft tissue infections: 2014 update by the Infectious Diseases Society o=
f America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59=
(2):e10-e52. doi:10.1093/cid/ciu296<span class=3D"pubmed-id"> [PubMed <a id=
=3D"24947530" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/24947530/pubmed">2494=
7530</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22379071">
                 =20
                     <a name=3D"22379071"></a>Taccetti G, Bianchini E, Cari=
ani L, et al. Early antibiotic treatment for <i>Pseudomonas aeruginosa</i> =
eradication in patients with cystic fibrosis: a randomised multicentre stud=
y comparing two different protocols. <i>Thorax</i>. 2012;67(10):853-859. do=
i:10.1136/thoraxjnl-2011-200832<span class=3D"pubmed-id"> [PubMed <a id=3D"=
22379071" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colis=
tin-colistimethate-drug-information/abstract-text/22379071/pubmed">22379071=
</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-34864936">
                 =20
                     <a name=3D"34864936"></a>Tamma PD, Aitken SL, Bonomo R=
A, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of Americ=
a guidance on the treatment of AmpC =CE=B2-lactamase-producing Enterobacter=
ales, carbapenem-resistant <i>Acinetobacter baumannii</i>, and <i>Stenotrop=
homonas maltophilia</i> infections. <i>Clin Infect Dis</i>. 2022a;74(12):20=
89-2114. doi:10.1093/cid/ciab1013<span class=3D"pubmed-id"> [PubMed <a id=
=3D"34864936" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/34864936/pubmed">3486=
4936</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-35439291">
                 =20
                     <a name=3D"35439291"></a>Tamma PD, Aitken SL, Bonomo R=
A, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of Americ=
a 2022 guidance on the treatment of extended-spectrum =CE=B2-lactamase prod=
ucing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE=
), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. ae=
ruginosa). <i>Clin Infect Dis</i>. 2022b;75(2):187-212. doi:10.1093/cid/cia=
c268<span class=3D"pubmed-id"> [PubMed <a id=3D"35439291" target=3D"_blank"=
 href=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-inf=
ormation/abstract-text/35439291/pubmed">35439291</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22935871">
                 =20
                     <a name=3D"22935871"></a>Tamma PD, Newland JG, Pannara=
j PS, et al. The use of intravenous colistin among children in the United S=
tates: results from a multicenter, case series. <i>Pediatr Infect Dis J</i>=
. 2013;32(1):17-22. doi:10.1097/INF.0b013e3182703790<span class=3D"pubmed-i=
d"> [PubMed <a id=3D"22935871" target=3D"_blank" href=3D"https://www.uptoda=
te.com/contents/colistin-colistimethate-drug-information/abstract-text/2293=
5871/pubmed">22935871</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-30576264">
                 =20
                     <a name=3D"30576264"></a>Thomas R, Velaphi S, Ellis S,=
 et al. The use of polymyxins to treat carbapenem resistant infections in n=
eonates and children. <i>Expert Opin Pharmacother</i>. 2019;20(4):415-422. =
doi:10.1080/14656566.2018.1559817<span class=3D"pubmed-id"> [PubMed <a id=
=3D"30576264" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/30576264/pubmed">3057=
6264</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20729233">
                 =20
                     <a name=3D"20729233"></a>Tramper-Stranders GA, Wolfs T=
F, van Haren Noman S, et al. Controlled Trial of Cycled Antibiotic Prophyla=
xis to Prevent Initial <i>Pseudomonas aeruginosa</i> Infection in Children =
With Cystic Fibrosis. <i>Thorax</i>. 2010;65(10):915-920.<span class=3D"pub=
med-id"> [PubMed <a id=3D"20729233" target=3D"_blank" href=3D"https://www.u=
ptodate.com/contents/colistin-colistimethate-drug-information/abstract-text=
/20729233/pubmed">20729233</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-16163635">
                 =20
                     <a name=3D"16163635"></a>Trotman RL, Williamson JC, Sh=
oemaker DM, et al. Antibiotic Dosing in Critically Ill Adult Patients Recei=
ving Continuous Renal Replacement Therapy. <i>Clin Infect Dis</i>. 2005, 41=
(8):1159-1166.<span class=3D"pubmed-id"> [PubMed <a id=3D"16163635" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/16163635/pubmed">16163635</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-30710469">
                 =20
                     <a name=3D"30710469"></a>Tsuji BT, Pogue JM, Zavascki =
AP, et al. International consensus guidelines for the optimal use of the po=
lymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), Eur=
opean Society of Clinical Microbiology and Infectious Diseases (ESCMID), In=
fectious Diseases Society of America (IDSA), International Society for Anti=
-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), a=
nd Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i=
>. 2019;39(1):10-39. doi:10.1002/phar.2209<span class=3D"pubmed-id"> [PubMe=
d <a id=3D"30710469" target=3D"_blank" href=3D"https://www.uptodate.com/con=
tents/colistin-colistimethate-drug-information/abstract-text/30710469/pubme=
d">30710469</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23989805">
                 =20
                     <a name=3D"23989805"></a>Tumbarello M, De Pacale G, Tr=
ecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment =
on the outcomes of microbiologically documented ventilator-associated pneum=
onia caused by colistin-only susceptible gram-negative bacteria. <i>Chest</=
i>. 2013;144(6):1768-1775.<span class=3D"pubmed-id"> [PubMed <a id=3D"23989=
805" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-c=
olistimethate-drug-information/abstract-text/23989805/pubmed">23989805</a>]=
</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-28203777">
                 =20
                     <a name=3D"28203777"></a>Tunkel AR, Hasbun R, Bhimraj =
A, et al. 2017 Infectious Diseases Society of America's clinical practice g=
uidelines for healthcare-associated ventriculitis and meningitis. <i>Clin I=
nfect Dis</i>. 2017;64(6):e34-e65.<span class=3D"pubmed-id"> [PubMed <a id=
=3D"28203777" target=3D"_blank" href=3D"https://www.uptodate.com/contents/c=
olistin-colistimethate-drug-information/abstract-text/28203777/pubmed">2820=
3777</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-15494903">
                 =20
                     <a name=3D"15494903"></a>Tunkel AR, Hartman BJ, Kaplan=
 SL, et al. Practice Guidelines for the Management of Bacterial Meningitis.=
 <i>Clin Infect Dis</i>. 2004;39(9):1267-1284.<span class=3D"pubmed-id"> [P=
ubMed <a id=3D"15494903" target=3D"_blank" href=3D"https://www.uptodate.com=
/contents/colistin-colistimethate-drug-information/abstract-text/15494903/p=
ubmed">15494903</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-20000886">
                 =20
                     <a name=3D"20000886"></a>Udy AA, Roberts JA, Boots RJ,=
 Paterson DL, Lipman J. Augmented renal clearance: implications for antibac=
terial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):=
1-16. doi:10.2165/11318140-000000000-00000<span class=3D"pubmed-id"> [PubMe=
d <a id=3D"20000886" target=3D"_blank" href=3D"https://www.uptodate.com/con=
tents/colistin-colistimethate-drug-information/abstract-text/20000886/pubme=
d">20000886</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-UKCF.1">
                 =20
                     <a name=3D"UKCF.1"></a>UK Cystic Fibrosis Trust Antibi=
otic Working Group. Antibiotic treatment for cystic fibrosis: 3rd edition. =
2009.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-FDA.1">
                 =20
                     <a name=3D"FDA.1"></a>US Food and Drug Administration =
(FDA). Information for Healthcare Professionals: Colistimethate (marketed a=
s Coly-Mycin M and generic products). FDA Alert June 28, 2007. <a target=3D=
"_blank" href=3D"http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyIn=
formationforPatientsandProviders/ucm124896.htm">http://www.fda.gov/Drugs/Dr=
ugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124896.h=
tm</a>. Updated August 14, 2013. Accessed January 31, 2014.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-25493971">
                 =20
                     <a name=3D"25493971"></a>Valachis A, Samonis G, Kofter=
idis DP. The role of aerosolized colistin in the treatment of ventilator-as=
sociated pneumonia: a systematic review and metaanalysis. <i>Crit Care Med<=
/i>. 2015;43(3):527-533.<span class=3D"pubmed-id"> [PubMed <a id=3D"2549397=
1" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-col=
istimethate-drug-information/abstract-text/25493971/pubmed">25493971</a>]</=
span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-27139161">
                 =20
                     <a name=3D"27139161"></a>VanDevanter DR, Flume PA, Mor=
ris N, Konstan MW. Probability of IV antibiotic retreatment within thirty d=
ays is associated with duration and location of IV antibiotic treatment for=
 pulmonary exacerbation in cystic fibrosis. <i>J Cyst Fibros</i>. 2016;15(6=
):783-790. doi:10.1016/j.jcf.2016.04.005<span class=3D"pubmed-id"> [PubMed =
<a id=3D"27139161" target=3D"_blank" href=3D"https://www.uptodate.com/conte=
nts/colistin-colistimethate-drug-information/abstract-text/27139161/pubmed"=
>27139161</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-32179149">
                 =20
                     <a name=3D"32179149"></a>Wacharachaisurapol N, Phasoms=
ap C, Sukkummee W, et al. Greater optimisation of pharmacokinetic/pharmacod=
ynamic parameters through a loading dose of intravenous colistin in paediat=
ric patients. <i>Int J Antimicrob Agents</i>. 2020;55(6):105940. doi:10.101=
6/j.ijantimicag.2020.105940<span class=3D"pubmed-id"> [PubMed <a id=3D"3217=
9149" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-=
colistimethate-drug-information/abstract-text/32179149/pubmed">32179149</a>=
]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-18606838">
                 =20
                     <a name=3D"18606838"></a>Wallace SJ, Li J, Rayner CR, =
Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceu=
tical products and solutions for administration to patients [published onli=
ne ahead of print July 7, 2008]. <i>Antimicrob Agents Chemother</i>. 2008;5=
2(9):3047-3051.<span class=3D"pubmed-id"> [PubMed <a id=3D"18606838" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/18606838/pubmed">18606838</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23201321">
                 =20
                     <a name=3D"23201321"></a>Wang JH, Lin PC, Chou CH, et =
al. Intraventricular antimicrobial therapy in postneurosurgical Gram-negati=
ve bacillary meningitis or ventriculitis: a hospital-based retrospective st=
udy. <i>J Microbiol Immunol Infect</i>. 2014;47(3):204-210. doi:10.1016/j.j=
mii.2012.08.028<span class=3D"pubmed-id"> [PubMed <a id=3D"23201321" target=
=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colistimetha=
te-drug-information/abstract-text/23201321/pubmed">23201321</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-Waters.1">
                 =20
                     <a name=3D"Waters.1"></a>Waters I, Wilcox P, Chilvers =
M, et al. Cystic fibrosis: care guidelines specific to new acquisition of p=
ulmonary bacteria. <a target=3D"_blank" href=3D"https://www2.gov.bc.ca/asse=
ts/gov/health/practitioner-pro/bc-guidelines/cystic-fibrosis/care_guideline=
s_specific_to_new_acquisition_of_pulmonary_bacteria.pdf">https://www2.gov.b=
c.ca/assets/gov/health/practitioner-pro/bc-guidelines/cystic-fibrosis/care_=
guidelines_specific_to_new_acquisition_of_pulmonary_bacteria.pdf</a>. Publi=
shed February 2018. Accessed October 12, 2022.</div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22576791">
                 =20
                     <a name=3D"22576791"></a>Winter MA, Guhr KN, Berg GM. =
Impact of various body weights and serum creatinine concentrations on the b=
ias and accuracy of the Cockcroft-Gault equation. <i>Pharmacotherapy</i>. 2=
012;32(7):604-612. doi:10.1002/j.1875-9114.2012.01098.x<span class=3D"pubme=
d-id"> [PubMed <a id=3D"22576791" target=3D"_blank" href=3D"https://www.upt=
odate.com/contents/colistin-colistimethate-drug-information/abstract-text/2=
2576791/pubmed">22576791</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-17214907">
                 =20
                     <a name=3D"17214907"></a>Yagmur R, Esen F. Intrathecal=
 colistin for treatment of <i>Pseudomonas aeruginosa</i> ventriculitis: rep=
ort of a case with successful outcome. <i>Crit Care</i>. 2006;10(6):428.<sp=
an class=3D"pubmed-id"> [PubMed <a id=3D"17214907" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/17214907/pubmed">17214907</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-30535100">
                 =20
                     <a name=3D"30535100"></a>Yahav D, Franceschini E, Kopp=
el F, et al; Bacteremia Duration Study Group. Seven versus 14 days of antib=
iotic therapy for uncomplicated gram-negative bacteremia: a noninferiority =
randomized controlled trial. <i>Clin Infect Dis</i>. 2019;69(7):1091-1098. =
doi:10.1093/cid/ciy1054<span class=3D"pubmed-id"> [PubMed <a id=3D"30535100=
" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-coli=
stimethate-drug-information/abstract-text/30535100/pubmed">30535100</a>]</s=
pan>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-24550334">
                 =20
                     <a name=3D"24550334"></a>Yapa SWS, Li J, Patel K, et a=
l. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colis=
tin methanesulfonate in cystic fibrosis patients: targeting advantage of in=
halational administration. <i>Antimicrob Agents Chemother</i>. 2014;58(5):2=
570-2579.<span class=3D"pubmed-id"> [PubMed <a id=3D"24550334" target=3D"_b=
lank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dru=
g-information/abstract-text/24550334/pubmed">24550334</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-22949160">
                 =20
                     <a name=3D"22949160"></a>Young D, Zobell J, Waters C, =
et al. Optimization of Anti-Pseudomonal Antibiotics for Cystic Fibrosis Pul=
monary Exacerbations: IV. Colistimethate Sodium. <i>Ped Pulmonol</i>. 2013;=
48(1):1-7.<span class=3D"pubmed-id"> [PubMed <a id=3D"22949160" target=3D"_=
blank" href=3D"https://www.uptodate.com/contents/colistin-colistimethate-dr=
ug-information/abstract-text/22949160/pubmed">22949160</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-35023664">
                 =20
                     <a name=3D"35023664"></a>Yurttutan S, Atalay BC. Short=
 and long term side effect of colistin treatment in preterm infants. <i>Tur=
k J Pediatr</i>. 2021;63(6):1108-1109. doi:10.24953/turkjped.2021.06.022<sp=
an class=3D"pubmed-id"> [PubMed <a id=3D"35023664" target=3D"_blank" href=
=3D"https://www.uptodate.com/contents/colistin-colistimethate-drug-informat=
ion/abstract-text/35023664/pubmed">35023664</a>]</span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-23335739">
                 =20
                     <a name=3D"23335739"></a>Ziaka M, Markantonis SL, Fous=
teri M, et al. Combined intravenous and intraventricular administration of =
colistin methanesulfonate in critically ill patients with central nervous s=
ystem infection. <i>Antimicrob Agents Chemother</i>. 2013;57(4):1938-1940. =
doi:10.1128/AAC.01461-12<span class=3D"pubmed-id"> [PubMed <a id=3D"2333573=
9" target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-col=
istimethate-drug-information/abstract-text/23335739/pubmed">23335739</a>]</=
span>
                  </div>
</li>
<li>
<div class=3D"reference" id=3D"lexi-content-ref-8879797">
                 =20
                     <a name=3D"8879797"></a>Zylberberg H, Vargaftig J, Bar=
bieux C, et al. Prolonged Efficiency of Secondary Prophylaxis With Colistin=
 Aerosols for Respiratory Infection Due to <i>Pseudomonas aeruginosa</i> in=
 Patients Infected With Human Immunodeficiency Virus. <i>Clin Infect Dis</i=
>. 1996;23(3):641-643.<span class=3D"pubmed-id"> [PubMed <a id=3D"8879797" =
target=3D"_blank" href=3D"https://www.uptodate.com/contents/colistin-colist=
imethate-drug-information/abstract-text/8879797/pubmed">8879797</a>]</span>
                  </div>
</li></ol></div><div id=3D"topicVersionRevision">Topic 8718 Version 292.0</=
div></div>
                                                              </div>
                </div>
           =20
        </section>
           =20
               =20
    </section>




</body></html>
